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ABSTRACT	Jonathan	V.	Todd:	HIV	and	Statin	Use	in	the	Women’s	Interagency	HIV	Study	(Under	the	direction	of	Stephen	R.	Cole)	With	the	provision	of	effective	antiretroviral	therapy	(ART)	for	HIV,	increasingly	the	interactions	between	HIV,	ART,	and	chronic	diseases	of	aging,	such	as	cardiovascular	disease,	are	of	interest.	Dyslipidemia	is	a	common	condition	found	in	HIV-infected	patients.	Reflecting	changing	national	guidelines,	treatment	of	dyslipidemia	with	statins	has	increased	in	the	US,	both	in	the	general	population	and	the	HIV-infected	population.	It	is	unknown	if	HIV-infected	patients	are	as	likely	to	initiate	statins	when	indicated,	in	comparison	to	HIV-uninfected	patients.	Regarding	the	efficacy	of	statins,	previous	work	has	shown	a	benefit	to	statin	use	for	LDL	cholesterol	lowering,	but	with	a	slightly	reduced	benefit	among	HIV-infected	patients.	However,	this	question	has	not	been	examined	extensively	in	women.	We	examined	the	effect	of	HIV	serostatus	on	the	use	and	efficacy	of	statins	in	the	Women’s	Interagency	HIV	Study	(WIHS),	a	prospective	multicenter	cohort	of	HIV-infected	women	and	matched	HIV-uninfected	controls	in	the	US.	Among	4607	women	in	the	WIHS,	473	had	an	indication	by	Adult	Treatment	Panel	(ATP)	III	guidelines	and	did	not	have	prior	statin	use.	Compared	to	HIV-uninfected	women,	the	weighted	hazard	ratio	for	initiation	of	a	statin	for	HIV-infected	women	was	0.95	(95%	confidence	interval	(CI):	0.63,	1.44),	and	the	two-year	risk	ratio	was	0.82	(95%	CI:	0.39,	1.24).	We	found	little	evidence	of	a	difference	by	HIV	serostatus,	in	the	uptake	of	statins	in	our	cohort.	Among	both	HIV-infected	and	uninfected	women,	the	prevalence	of	statin	
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indication	increased	nearly	three-fold	when	applying	the	2013	American	College	of	Cardiology/American	Heart	Association	guidelines	instead	of	the	2001	ATP	III	guidelines.	We	estimated	the	effect	of	HIV	on	the	efficacy	of	statins,	as	measured	by	changes	in	LDL	cholesterol	from	baseline	(prior	to	statin	initiation)	to	approximately	one	year	of	follow-up.	Out	of	659	statin	initiators,	481	(73%)	were	HIV-infected.	LDL	cholesterol	was	reduced	after	approximately	one	year	in	both	exposure	groups.	After	adjustment	the	change	in	LDL	cholesterol	for	HIV-infected	women	was	-15.1	mg/dL,	and	in	HIV-uninfected	women	it	was	-17.4	mg/dL.	The	difference	in	mean	change	was	2.3	mg/dL	(95%	CI:	-5.4,	10.1).		
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CHAPTER	1:	CRITICAL	REVIEW	OF	THE	LITERATURE	
1.1	HIV	and	Dyslipidemia	Patients	living	with	HIV	today	experience	a	dramatically	reduced	risk	of	HIV-related	morbidity	and	mortality,	in	large	part	due	to	the	administration	of	combination	antiretroviral	therapy	(ART)	(1).	ART	has	been	shown	to	control	viremia	in	patients	(2),	as	well	as	helping	reverse	the	immunological	decline	previously	associated	with	the	disease	(3).	HIV-positive	patients	are	living	longer,	and	HIV	clinicians	have	increasingly	been	confronted	with	the	metabolic	consequences	of	ART	decisions	and	their	effect	on	the	risk	for	cardiovascular	outcomes	(4-5).	In	particular,	dyslipidemia	is	a	condition	that	may	result	from	the	effects	of	both	HIV	disease	itself	and	ART.		
1.2	Prevalence	and	Incidence	of	Dyslipidemia	in	HIV	Patients	Total	cholesterol	(TC),	low-density	lipoprotein	cholesterol	(LDL-C),	high-density	lipoprotein	cholesterol	(HDL-C),	and	triglycerides	are	some	of	the	most	commonly	measured	lipid	values,	and	when	taken	together	in	context,	provide	a	picture	of	a	patient’s	lipid	health.	Guidelines	for	the	management	of	dyslipidemias	have	been	provided	by	the	National	Cholesterol	Education	Program;	these	guidelines	have	been	applied	to	HIV-positive	populations	(4,6).	More	recently	in	2013,	new	guidelines	were	published	by	the	American	Heart	Association	and	the	American	College	of	Cardiology	(7).	These	new	
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guidelines	dramatically	increased	the	indication	for	lipid	lowering	therapy	in	many	patients.	Table	1.1	includes	studies	that	have	measured	markers	of	dyslipidemia	in	HIV-positive	patients	(8-17).	There	are	a	wide	variety	of	study	designs,	including	randomized	clinical	trials,	prospective	cohorts,	retrospective	cohorts,	and	cross-sectional	designs.	In	most	cases	studies	reported	a	change	in	lipid	level	from	baseline,	or	in	the	case	of	cross-sectional	studies,	the	actual	lipid	value.	Prevalence	was	reported	in	two	studies,	while	incidence	was	not	found.	Overall,	the	use	of	ART	was	associated	with	an	increase	in	all	serum	lipid	values	other	than	HDL	cholesterol.	Stavudine,	a	thymidine	analogue	nucleoside	reverse	transcriptase	inhibitor	(NRTI),	was	particularly	associated	with	poor	lipid	outcomes.	Llibre	(2006)	demonstrated	that	switching	from	stavudine	to	tenofovir	was	associated	with	lower	triglycerides,	LDL,	and	total	cholesterol	(12).	Tenofovir	disoproxil	fumarate,	currently	a	preferred	NRTI	for	use	in	ART,	was	associated	with	lower	lipid	levels	after	switching	from	both	stavudine	(12),	and	the	combination	of	abacavir/lamivudine	(8).	Among	the	different	antiretroviral	classes,	protease	inhibitor-based	regimens	resulted	in	the	worst	lipid	profiles.	Three	studies	merit	specific	attention;	two	due	to	their	large	sample	size	and	a	third	because	of	its	design.	Friis-Möller	et	al.	reported	in	2003	on	17,852	patients	from	the	Data	Collection	on	Adverse	Events	of	Anti-HIV	Drugs	(D:A:D)	cohort,	a	large	European	prospective	cohort.	They	found	baseline	total	cholesterol	and	triglyceride	values	were	highest	in	PI-containing	regimens;	in	particular,	those	with	both	a	PI	and	a	non-nucleoside	reverse	transcriptase	inhibitor	(NNRTI).	The	major	strength	of	this	study	was	its	large	sample	size,	which	dwarfed	most	of	the	other	studies	in	this	review	(14).	Crane	et	al.	
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reported	in	2011	on	a	large	cohort	from	the	USA,	the	Center	for	AIDS	Research	Network	of	Integrated	Clinical	Systems	(CNICS)	cohort	(13).	Rapid	increases	in	lipid	values	were	found	within	one	year	of	therapy	initiation	which	began	to	attenuate	after	the	first	year.	Tenofovir	showed	the	best	lipid	profile	among	NRTIs	in	this	study.	The	AIDS	Clinical	Trials	Group	Study	A5152s	was	a	randomized	clinical	trial	comparing	the	lipoprotein	profiles	of	three	different	ARV	regimens	(NRTI,	NNRTI,	and	PI-sparing	regimens)	after	24	weeks	in	six	centers	in	the	USA	(10).	Total	cholesterol	was	significantly	higher	from	baseline	in	all	three	study	arms,	with	the	greatest	increase	in	the	efavirenz	+	lopinavir/ritonavir	NRTI-sparing	arm	(Median	increase:	65	mg/dL).	Increases	in	triglycerides,	direct	LDL	cholesterol,	and	HDL	cholesterol	were	also	found.	This	study	provided	additional	evidence	that	PI-containing	regimens	can	be	associated	with	poorer	lipid	profiles.	Research	on	dyslipidemia	in	the	developing	world	has	been	limited,	but	in	general,	trends	in	lipid	markers	are	similar	to	those	in	the	USA	and	Europe	(18-22).	Several	African	studies	demonstrated	that	dyslipidemia	is	occurring	as	a	result	of	ART	scale-up.	One	in	particular,	Armstrong	et	al.	was	a	Tanzanian	cross-sectional	study	notable	for	its	large	size	(N=12,513)	that	found	relatively	high	levels	for	HIV-positive	patients	at	diagnosis	(HDL	cholesterol	<40mg/dL:	67%;	triglycerides	>150mg/dL:	28%)	(18).	A	smaller	prospective	cohort	study	in	Uganda	(N=374)	found	increases	in	several	lipid	parameters	after	two	years	of	ART	(HDL:	19	mg/dL;	LDL:	26	mg/dL;	total	cholesterol:	31	mg/dL)	(19).	Overall,	similar	trends	were	found	in	African	studies	of	dyslipidemia.	
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1.3	Antiretroviral	Therapy	and	Lipid	Lowering	Therapy	Treatment	of	dyslipidemia	in	the	general	population	includes	dietary	changes,	increased	moderate	exercise,	increased	intake	of	soluble	fiber,	and	lipid	lowering	drugs	such	as	statins	(4).	Unfortunately	for	the	HIV-positive	population,	there	exist	significant	interactions	between	ART	and	many	statins,	particularly	with	protease	inhibitors.	Table	1.2,	adapted	from	Nachega’s	comprehensive	review	on	drug-drug	interactions	with	HIV	ART,	notes	the	major	interactions	between	antiretrovirals	and	statin	drugs	(23).	Many	such	interactions	result	from	competitive	inhibition	of	the	isoenzyme	CYP450	3A4.	Simvastatin,	considered	a	primary	treatment	option	for	many	patients	in	the	general	population,	is	contraindicated	for	use	with	PIs	due	to	dangerously	high	bioavailability	of	simvastatin	due	to	competitive	inhibition	by	the	PI.	Such	high	levels	of	simvastatin	can	result	in	muscle	damage,	including	possible	rhabdomyolysis.	Typically	HIV-positive	patients	receive	pravastatin,	pitavastatin,	or	low	dose	atorvastatin	or	rosuvastatin,	with	careful	clinical	monitoring.	Additionally	clinicians	may	choose	other	types	of	ART,	such	as	NNRTI-based	therapy,	to	avoid	potential	interactions	with	statin	therapy.			
1.4	Risk	Factors	for	Dyslipidemia	LDL	cholesterol	is	considered	the	most	atherogenic	lipid	protein	and	is	the	most	frequent	target	for	intervention	(6).	Table	1.3	shows	general	risk	factors	for	LDL	dyslipidemia,	adapted	from	the	ATP	III	guidelines.	In	addition	to	those	risk	factors	specific	to	the	general	population,	as	detailed	in	Table	1.1,	there	remain	ART	specific	risks.	ART	in	general	has	been	shown	to	increase	lipid	levels,	while	specific	drugs	and	classes	have	increased	propensities	for	raising	lipid	levels.		Protease	inhibitors,	as	a	class,	tend	to	result	
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in	increased	lipid	values	(10,14-15).	The	NRTI	stavudine	has	been	associated	in	multiple	studies	with	an	increased	risk	of	dyslipidemia	(12,16).	Fortunately	clinicians	have	alternatives,	such	as	NNRTIs	and	tenofovir	disoproxil	fumarate,	to	these	particular	drugs	and	classes	and	have	successfully	switched	therapy	while	maintaining	virologic	suppression	(8).	A	recent	review	by	Dube	et	al.	outlined	the	particular	drugs	within	each	class	whose	use	has	been	shown	to	result	in	a	higher	risk	of	dyslipidemia;	among	the	protease	inhibitors,	fosamprenavir-ritonavir,	lopinavir-ritonavir,	and	tipranavir-ritonavir	(4).	Of	note,	lopinavir-ritonavir	is	now	considered	an	“alternative	regimen”	rather	than	a	“preferred	regimen”	in	ART	guidelines	partially	because	of	this	higher	risk	of	lipid	complications	(24-25).
1.5	Changing	US	Guidelines	for	Lipid	Lowering	Therapy		In	2001	the	National	Cholesterol	Education	Program	released	the	Adult	Treatment	Panel	(ATP)	III	guidelines,	which	expanded	the	indication	for	lipid	lowering	therapy	in	the	general	population	(6).	These	recommendations	focused	on	the	use	of	intensive	lipid	lowering	therapy	for	patients	with	multiple	risk	factors	for	coronary	heart	disease.	ATP	III	informed	clinical	practice	throughout	our	study	period.	In	2013	the	American	College	of	Cardiology	(ACC)	and	the	American	Heart	Association	(AHA)	provided	a	revision	of	guidelines	for	lipid	lowering	therapy	(7).	As	with	ATP	III	before,	the	2013	ACC/AHA	guidelines	increased	the	aggressiveness	of	lipid	lowering	therapy,	and	provided	new	sex-	and	race-specific	pooled	cohort	equations	for	the	assessment	of	ten-year	atherosclerotic	cardiovascular	disease	(ASCVD)	risk.	These	guidelines	have	provoked	controversy,	as	some	clinicians	have	been	resistant	to	more	aggressive	therapy	with	statins	and	other	lipid	
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lowering	drugs	(26).	To	date,	research	has	been	limited	on	how	the	changing	guidelines	affect	the	proportions	of	HIV	populations	who	would	now	be	indicated	for	statin	use.	
1.6	Statin	Use	in	HIV	Patients	As	guidelines	have	recommended	statin	therapy	be	expanded,	use	in	the	US	has	increased.	A	recent	National	Health	and	Nutrition	Examination	Survey	(NHANES)	study	from	2005-2010	found	that	the	2013	ACC/AHA	guidelines	increased	the	proportion	of	adults	with	an	indication	for	statin	use	to	49%,	from	37.5%	with	the	ATP	III	guidelines	(27).	Statin	use	in	a	US	Medicare	population	rose	from	4%	in	1992	to	41%	in	2008	(28).	The	prevalence	of	therapy	for	atherosclerotic	cardiovascular	disease	in	a	study	in	a	New	York	City	HIV	clinic	was	extremely	high,	with	90%	of	patients	taking	at	least	one	drug	for	dyslipidemia,	and	75%	receiving	therapy	for	hypertension	(29).	A	recent	paper	by	Silverberg	et	al.	looked	at	the	effectiveness	of	statins	for	HIV	infected	patients,	in	comparison	to	HIV	uninfected	patients,	in	a	Kaiser	Permanente	cohort	in	California	(30).	For	HIV	infected	patients,	LDL	cholesterol	decreased	by	26%,	in	comparison	to	a	28%	reduction	in	HIV	uninfected	patients.	The	study	was	primarily	in	men,	however,	and	could	not	generalize	their	findings	to	women.			Notable	studies	of	statin	use	and	efficacy	in	HIV	patients	are	listed	in	Table	1.4	(30-34).	Most	studies	compared	the	effects	of	different	statins	on	lipid	changes	(31-33),	while	one	trial	examined	markers	of	vascular	inflammation	(34).	Two	studies	found	greater	LDL	cholesterol	reductions	among	rosuvasatin	and	atorvastatin	users	in	comparison	to	pravastatin	users	(31-32).	A	small	randomized	controlled	trial	of	rosuvastatin	vs.	placebo	found	no	difference	in	markers	of	vascular	inflammation;	however,	the	authors	did	report	
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that	rosuvastatin	therapy	did	reduce	levels	of	Lp-PLA2,	an	enzyme	that	is	a	marker	of	vascular	inflammation	(34).	
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TABLE	1.1:	Markers	of	dyslipidemia	among	HIV-positive	patients	in	the	USA,	Europe,	and	Australia	Study,	Year	 Study	Type	 Study	Population	 N	 Total	Cholesterola	 LDL	Cholesterola	 Triglyceridesa	 Remarks	Behrens,	2012	 Open-label	RCTb	 Patients	with	elevated	total	cholesterol,	switching	from	ABC/3TC	to	TDF/FTCb	 85	 TDF/FTC:	-28	 ---	 ---	 Lower	median	cholesterol	in	TDF/FTC	group	after	switch	Taiwo,	2011	 Prospective	cohort	 ART-naïve,	beginning	DRV/ritonavir	+	RALb	 112	 30	 17	 Increases	in	TC,	LDL-C,	and	triglycerides	on	NRTI-sparing	regimenbStein,	2008	 RCT	 ART-naive	 82	 NRTI-sparing:	65	NNRTI-sparing:	21	PI-sparing:	18	 NRTI-sparing:	26	NNRTI-sparing:	7	PI-sparing:	6	 NRTI-sparing:	83	NNRTI-sparing:	72	PI-sparing:	22	 Highest	lipid	increases	in	NRTI-sparing	group	Riddler,	2007	 Retrospective	cohort	 Homosexual/bisexual	men,	ART-naïve	 304	 42	 22	 ---	 Maximum	lipid	increases	2-3	years	after	ART	initiation	Llibre,	2006	 Prospective	cohort	 Patients	on	stable	ART,	switching	from	d4Tb	to	TDF	 352	 -17.5 -8.1 -35 Lower	median	lipid	values	after	switch	from	d4T	to	TDF	Crane,	2011	 Prospective	cohort	 PI/NNRTI-naive	 2,267	 Baseline:	128	12	months:	153	36	months:	153	 Baseline:	88	12	months:	98	36	months:	97	 Baseline:	120	12	months:	145	36	months:	149	 Rapid	increases	in	lipid	values	within	one	year	of	therapy;	levels	off	after	a	year.	Tenofovir	had	best	lipid	profile	Friis-Moller,	2003	 Cross-sectional	 General	HIV+	 17,852	 ART-naïve:	170	NNRTI:	205	PI:	205	PI/NNRTI:	228	
---	 ARV-naïve:	115	NNRTI:	142	PI:	168	PI/NNRTI:	221		
Baseline	TC	and	triglyceride	levels	were	highest	in	the	PI/NNRTI	group	
Saint-Marc,	2000	 Cross-sectional	 Men	 154	 ART-naïve:	184	NRTI:	188	PI:	230	 ART-naïve:	114	NRTI:	111	PI:	137	 ART-naïve:	115	NRTI:	173		PI:	273	 Lipid	profile	much	worse	for	patients	on	PI	therapy	Galli,	2002	 Prospective	cohort	 NOT	ART-naïve;	no	prior	lipodystrophy	 335	 11	 ---	 23	 Risk	of	hypertriglyceridemia	higher	in	d4T-treated	patients	Chêne,	2002	 RCTc	 ART-naive	 120	 40	 ---	 25	 Relatively	high	levels	of	dyslipidemia	at	baseline	a	Median	values	in	mg/dL	b	Acronyms:	RCT	–	randomized	clinical	trial;	ABC	–	abacavir;	3TC	–	lamivudine;	TDF	–	tenofovir	disoproxil	fumarate;	FTC	–	emtricitabine;	ACTG	–	AIDS	Clinical	Trials	Group	(22	sites	in	USA);		ART	–	antiretroviral	therapy;	DRV	–	darunavir;	RAL	–	raltegravir;	TC	–	total	cholesterol;	LDL	–	low	density	lipoprotein;	CNICS	–	Center	for	AIDS	Research	Network	of	Integrated	Clinical	Systems;		d4T	–	stavudine;	ddI	-	didanosine	c	RCT	for	6	months,	followed	by	24	months	of	prospective	follow-up
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TABLE	1.2:	Drug–drug	interactions	with	antihyperlipidemic	agentsa,b	Drug	interaction	with	antiretrovirals	 Management	recommendations	Atorvastatin	 Atorvastatin	AUC	↑	2.5,	5.8,	and	9.4-fold	with	FPV/r,	LPV/r,	and	TPV/r	coadministration.	Atorvastatin	AUC	↓	43%	with	EFV	co-administration.	 Avoid	TPV/r	with	atorvastatin	coadministration.	Other	PI/r:	start	with	atorvastatin	10mg	once	daily,	and	then	titrate	to	effect.	Do	not	exceed	atorvastatin	20mg	with	DRV/r,	FPV/r,	SQV/r.	EFV,	NVP,	ETR:	higher	atorvastatin	dose	may	be	needed.	Lovastatin	 Strong	CYP3A4	inhibitor	(e.g.	itraconazole)	significantly	increases	lovastatin	concentrations	20-fold.	PI/r	may	also	significantly	increase	lovastatin	concentrations.	 PI/r:	contraindicated	Pitavastatin	 DRV/r	and	LPV/r	decrease	pitavastatin	AUC	26	and	20%,	respectively.	ATV	increases	pitavastatin	AUC	31%.	 PI/r:	use	standard	dose	Pravastatin	 SQV/r	and	EFV	decrease	pravastatin	AUC	50	and	40%,	respectively.	LPV/r	and	DRV/r	increase	pravastatin	AUC	33%	and	81%,	respectively.	 Higher	pravastatin	dose	may	be	needed	with	SQV/r	and	EFV	co-administration.	With	DRV/r	coadministration,	use	with	close	monitoring	for	adverse	events.	Rosuvastatin	 TPV/r,	LPV/r,	ATV/r	increase	rosuvastatin	AUC	37,	110,	and	213%,	respectively.	 PI/r:	start	with	rosuvastatin	5mg	once	daily,	then	titrate	to	effect.	Maximum	recommended	rosuvastatin	dose	10mg/day	with	LPV/r	and	ATV/r	co-administration.	Simvastatin	 SQV/r	increases	simvastatin	AUC	31-fold.	EFV	decreases	simvastatin	AUC	58%.	 PI/r:	contraindicated;	EFV,	NVP,	ETR:	higher	simvastatin	dose	may	be	needed.	a	NOTE:	Table	adapted	from	Nachega	et	al.,	“Antiretroviral	therapy	adherence	and	drug-drug	interactions	in	the	aging	HIV	population.”19	b	Abbreviations:	ATV,	atazanavir;	ATV/r,	atazanavir/ritonavir;	AUC,	area	under	the	plasma	concentration	time	curve;	DRV/r,	darunavir/	ritonavir;	EFV,	efavirenz;	ETR,	etravirine;	FPV/r,	fosamprenavir/ritonavir;	LPV/r,	lopinavir/ritonavir;	NVP,	nevirapine;	PI/r,	protease	inhibitor	/ritonavir;	TPV/r,	tipranavir/	ritonavir;	SQV/r,	saquinavir/ritonavir.	
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TABLE	1.3:	Major	risk	factors	that	modify	LDL	goals*	Cigarette	smoking	Hypertension	(Blood	pressure	≥140/90	mmHg	or	on	antihypertensive	medication	Low	HDL	cholesterol	(<40	mg/dL)	Family	history	of	premature	coronary	heart	disease	(CHD	in	male	first	degree	relative	<55	years;	CHD	in	female	first	degree	relative	<65	years)	Age	(men	≥	45	years;	women	≥	55	years)	*Table	adapted	from	the	Executive	Summary	of	the	Third	Report	of	the	National	Cholesterol	Education	Program	(NCEP)Expert	Panel	on	Detection,	Evaluation,	and	Treatment	of	High	Blood	Cholesterol	in	Adults3
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TABLE	1.4:	Studies	involving	statin	use	in	HIV	infected	patients	Study,	Year	 Location	 Study	Type	 Study	Population	 N	 Comparison	 LDL	Cholesterol	or	total	cholesterola	 Remarks	Silverberg,	2009	 USA,	Kaiser	Permanente	 Retrospective	cohort	 New	users	of	statins	 829	HIV+,	6941	HIV-	 HIV	serostatus	 LDL	cholesterol	HIV+:	-25.6%	HIV-:	-28.3%	 LDL/triglycerides	reduction	smaller	in	HIV+	group.	Limited	number	of	women.	Lo,	2015	 USA	 RCT	 HIV+	with	subclinical	coronary	atherosclerosis	 40	 Atorvastatin	vs.	placebo	 LDL	cholesterol	(mean)	Atorvastatin:	-39mg/dL	Placebo:	12mg/dL	 No	difference	between	statin	arm	and	placebo	on	aterial	inflammation	of	the	aorta	Eckard,	2014	 USA	 RCT	 HIV+	w/fasting	LDL	≤130	mg/dL		 147	 Rosuvastatin	vs.	placebo	 LDL	cholesterol	Rosuvastatin:	-28%	Placebo:	4%	 Trial	was	designed	to	look	at	markers	of	vascular	inflammation,	no	difference	between	groups.	Singh,	2011	 USA,	CNICS	 Retrospective	cohort	 New	users	of	statins	 700	 Pravastatin	vs.	atorvastatin	vs.	rosuvastatin	 LDL	cholesterol	Pravastatin:	-12mg/dL	Atorvastatin:	-26mg/dL	Rosuvastatin:	-23mg/dL	
Atorvastatin	and	rosuvastatin	more	effective	for	lipid	lowering	than	pravastatin	Aslangul,	2010	 France	 Open-label	RCTb	 HIV+,	ritonavir-boosted	PI	users	 83	 Rosuvastatin	10mg	vs.	pravastatin	40mg	 LDL	cholesterol	Rosuvastatin:	-37%	Pravastatin:	-19%	 LDL/triglycerides	reduction	greater	in	rosuvastatin	arm	Bonnet,	2004	 France	 Prospective	cohort	 HIV+,	PI	or	NNRTI-based	ART,	elevated	lipids	 245	 Statins	vs.	fibrates	 Total	cholesterol	Statins:	-13%	Fibrates:	-	7%	 Results	reflect	the	indications	for	each	type	of	drug	a	Median	values	in	mg/dL	b	Acronyms:	RCT	–	randomized	clinical	trial;	ART	–	antiretroviral	therapy;	LDL	–	low	density	lipoprotein;	CNICS	–	Center	for	AIDS	Research	Network	of	Integrated	Clinical	Systems;	HIV	–	human	immunodeficiency	virus;	NNRTI	–	non-nucleoside	reverse	transcriptase	inhibitor;	PI	–	protease	inhibitor;	
11
CHAPTER	2:	STATEMENT	OF	SPECIFIC	AIMS	
2.1	Statement	of	Specific	Aims	and	Hypotheses	The	overall	goal	of	this	study	is	to	explore	statin	use	in	the	understudied	population	of	HIV+	women.	The	aims	are:			
2.1.1	Specific	Aim	1	Our	first	specific	aim	is	to	describe	the	effect	of	HIV	serostatus	on	disparities	in	lipid	management,	as	measured	by	indicated	and	realized	statin	use	among	women	in	the	WIHS.	New	use	of	statins	will	be	examined	by	HIV	serostatus,	age,	calendar	year,	and	(among	HIV+)	ART	regimen.		We	hypothesize	that	HIV+	women	will	be	less	likely	to	receive	statins	when	indicated,	in	comparison	to	HIV-	women	and	that	new	statin	use	will	be	more	likely	for	HIV-	women,	older	women,	and	women	receiving	protease	inhibitors	(PI)	(for	HIV+),	and	will	increase	over	calendar	time.	
2.1.2	Specific	Aim	2	Among	new	users	of	statins,	our	second	specific	aim	is	to	estimate	the	effect	of	HIV	serostatus	and	ART	regimen	(among	HIV+)	on	1	and	2	year	lipid	values	changes	(i.e.	LDL	cholesterol,	triglycerides,	HDL	cholesterol,	and	total	cholesterol).		
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We	hypothesize	that	HIV+	new	users	of	statins	will	have	smaller	decreases	in	LDL	cholesterol	than	HIV-	new	users,	due	to	effects	of	the	virus	and	ART.	Among	HIV+	patients,	we	hypothesize	that	new	users	of	statins	concurrently	on	PI-based	therapy	will	have	smaller	decreases	in	LDL	cholesterol	compared	to	new	users	of	statins	concurrently	on	other	types	of	ART,	due	to	PI-mediated	increases	in	cholesterol.	
2.2	Significance	With	HIV+	patients	living	longer	the	management	of	HIV	has	shifted	in	part	from	the	prevention	and	treatment	of	opportunistic	conditions	to	the	prevention	and	treatment	of	non-HIV-associated	diseases	associated	with	aging	(4-5,	8-17,	35-36).	Such	non-HIV	associated	conditions	are	emerging	as	the	leading	causes	of	mortality	among	persons	living	with	HIV,	and	among	these,	cardiovascular	disease	(CVD)	has	become	a	major	health	threat.	In	cohort	studies	of	persons	living	with	HIV	CVD	has	been	found	to	be	responsible	for	10-15%	of	deaths	(37-40).	In	a	population-based	cohort	analysis	of	deaths	among	HIV+	persons	in	New	York	City	between	1999	and	2004,	CVD	was	the	leading	non-HIV-related	and	non-substance	abuse-related	cause	of	death,	accounting	for	23%	of	these	deaths	(37).	Importantly,	the	relative	risk	of	CVD	was	higher	for	women	compared	to	men.	The	age-adjusted	mortality	rate	for	acute	myocardial	infarction	was	5.0/100,000	for	women	compared	to	3.8/100,000	for	men.	Among	women	in	the	high-risk	heterosexual	category,	CVD	accounted	for	36%	of	all	non–HIV-related	deaths,	primarily	due	to	chronic	ischemic	heart	disease.		CVD	is	often	preventable	with	modification	of	lifestyle	and	medical	interventions.	A	cornerstone	of	CVD	prevention	is	the	reduction	in	atherogenic	lipids,	chiefly	LDL	
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cholesterol,	and	the	most	efficacious	and	potent	LDL-reducing	therapies	are	HMG-reductase	inhibitors	(i.e.,	statins).	Guidelines	for	the	treatment	of	dyslipidemia	for	the	general	population	apply	to	HIV+	patients.	While	use	of	statins	by	HIV+	patients	has	been	documented	to	be	increasing,	it	remains	unclear	if	these	medications	are	being	prescribed	equally	to	those	with	and	without	HIV	infection,	particularly	women,	when	indicated.	Disparities	in	care	for	women	are	well	documented	(41-49),	and	have	been	shown	to	extend	to	treatment	of	CVD	(50-55).	Further,	Blacks	and	Hispanics	may	be	less	likely	to	receive	treatment	for	dyslipidemia	in	comparison	to	whites	(56-57).	That	such	disparities	in	CVD	treatment	and	prevention	extend	to	HIV	management	are	supported	by	a	number	of	recently	reported	studies	that	find	HIV+	patients	are	under-prescribed	preventative	care	including	statin	therapy	and	aspirin	for	CVD	prevention.	Unfortunately,	these	studies	include	relative	few	women	and	have	not	examined	outcomes	by	gender.	It	remains	unclear	to	what	extent	HIV+	women	experience	barriers	to	access	to	preventative	care	for	CVD.		 In	addition	to	the	potential	for	disparities	in	access	to	statins,	there	are	limited	data	regarding	the	comparative	efficacy	of	these	agents	between	HIV+	and	HIV-	individuals.	Responses	to	lipid	lowering	therapy	for	medication-	or	viral-associated	increases	in	cholesterol	and	triglycerides	may	not	be	as	robust	as	those	seen	in	more	endogenous	dyslipidemia.	Further,	drug-drug	interactions	and	differential	adverse	effect	patterns	could	lead	to	differential	responses	to	statin	therapy.		Given	the	risk	of	CVD	among	HIV+	women	and	the	documented	disparities	in	health	care,	including	CVD	prevention,	for	women,	minorities,	and	those	living	with	HIV,	it	is	imperative	that	assessments	of	differential	access	to	statin	therapy	be	examined.	The	
14
proposed	analyses	will	compare	use	of	and	response	to	statin	therapy	among	women	with	and	without	HIV.	
2.3	Innovation	
2.3.1	Importance	of	Research	Questions	Disparities	in	health	care	for	HIV+	women,	particularly	regarding	cardiovascular	treatment,	are	well	documented.	Similar	gaps	in	the	literature	for	HIV+	women	exist.	We	will	examine	two	novel	research	questions	related	to	statin	treatment	for	HIV+,	comparing	seropositive	women	to	HIV-	women:	differential	access	to	statins,	and	the	effectiveness	of	those	statins	in	lowering	lipid	values.	While	some	of	these	questions	have	been	addressed	for	HIV+	men,	they	have	not	been	addressed	in	women.	To	compare	statin	use	in	women	by	HIV	serostatus,	we	need	a	HIV	longitudinal	cohort	with	HIV-	controls	and	extensive	information	on	medication	use,	laboratory	results,	and	behaviors.	The	Women’s	Interagency	HIV	Study	(WIHS)	is	a	longitudinal	cohort	that	contains	data	needed	to	address	questions	of	statin	use	within	HIV+	women	(58).	Based	in	multiple	urban	sites	across	the	USA,	the	WIHS	began	recruitment	of	subjects	in	1994.	WIHS	participants	complete	biannual	study	visits,	including	an	extensive	interview	for	medication	history,	behavioral	risk	factors,	and	HIV-related	outcomes.	Blood	is	drawn	for	HIV	and	non-HIV	related	lab	values.	As	of	September	2012,	the	WIHS	contains	longitudinal	information	on	4124	patients,	with	three	distinct	recruitment	periods	(1994/1995,	2001/2002,	and	2011/2012).	Lipid	values	were	regularly	recorded	beginning	in	1999.	Because	it	contains	detailed	longitudinal	information	on	behavioral	characteristics	such	as	smoking	and	alcohol	abuse,	laboratory	and	medication	history	information,	and	a	group	of	
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HIV-	controls,	the	WIHS	is	ideally	suited	to	study	questions	related	to	the	effect	of	HIV	on	statin	use.	
2.3.2	Targeted	Maximum	Likelihood	Estimation	To	answer	our	study	questions,	we	will	use	two	methods	to	estimate	changes	in	biomarkers	between	the	beginning	of	statin	use	and	a	range	of	subsequent	follow-up	times:	linear	regression,	and	targeted	maximum	likelihood	estimation	(TMLE).	TMLE	is	an	innovative	data-adaptive	estimation	technique	that	incorporates	machine-learning	algorithms	with	standard	parametric	regression	models	(59-60).	The	first	step	implements	the	SuperLearner	procedure	to	generate	an	initial	estimate	of	the	probability	of	the	outcome,	conditional	on	treatment	and	measured	covariates	(61).	Cross	validation	is	used	to	create	the	best	weighted	combination	of	algorithms,	as	measured	by	mean	square	error,	of	the	specified	machine	learning	and	parametric	regression	equations.	The	SuperLearner	estimate	is	guaranteed	to	be	as	least	as	efficient	as	any	single	candidate	estimator	or	combination	of	estimators	(60-61).	This	initial	estimate	is	then	altered	by	use	of	a	so-called	“clever	covariate”,	developed	by	a	second	model	for	the	probability	of	treatment,	conditional	of	measured	covariates.	Under	an	appropriate	set	of	identification	assumptions	(i.e.,	consistency,	exchangeability,	positivity)	the	TMLE	produces	an	asymptotically	consistent	estimate	of	the	causal	parameter	(62).		The	TMLE	procedure	has	several	advantages	over	standard	methods:	it	is	double	robust,	provides	a	marginal	effect	estimate,	allows	the	incorporation	of	an	expanding	library	of	machine-learning	algorithms	and	multiple	candidate	parametric	models,	and	increases	estimation	efficiency	by	targeting	the	parameter	of	interest.	Gains	in	efficiency	
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are	realized	by	maximizing	the	bias/variance	tradeoff	solely	for	the	target	parameter,	rather	than	nuisance	parameters	such	as	confounders.	Simulation	studies	have	demonstrated	TMLE’s	efficiency	in	comparison	to	standard	regression	techniques	(59-60,	63).	Despite	theoretical	advantages,	TMLE	has	yet	to	be	used	extensively	in	public	health	studies.	Our	study	will	increase	the	visibility	of	these	methods,	which	allow	for	causal	effect	estimation	under	a	series	of	assumptions.	
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CHAPTER	3:	METHODS	
3.1	Study	Population	The	Women’s	Interagency	HIV	Study	(WIHS)	is	a	prospective	observational	cohort	of	HIV+	women	and	HIV-	controls,	designed	to	follow	the	natural	history	of	HIV	disease	within	women	(58).	With	a	rich	variety	of	behavioral,	medication,	and	laboratory	data,	as	well	as	HIV-	controls,	the	WIHS	is	an	excellent	data	source	for	longitudinal	research	questions	involving	HIV+	women.	Recruitment	of	study	patients	began	in	1994,	and	continues	today.	Over	4000	women	have	participated	in	the	WIHS,	with	approximately	75%	HIV+.	Patients	are	followed	at	six-month	intervals,	and	contribute	a	structured	interview	and	laboratory	samples.	HIV-	controls	are	tested	at	each	visit	for	changes	in	seropositivity.	Antiretroviral	regimen	history	and	concomitant	medications,	including	statins,	are	recorded	at	each	visit.	We	will	construct	a	longitudinal	exposure	history	for	patients	based	upon	their	response	to	a	question	about	statin	use	within	the	previous	six	months.	Table	3.1	contains	characteristics	about	the	general	WIHS	population.	
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TABLE	3.1:	General	WIHS	Population	Characteristics	at	Study	Entry	Characteristic	 Overall	(N=4582)	 HIV+	(N=3374)	 HIV-	(N=1208)	Age	 36	(30,	42)	 37	(31,	43)	 35	(27,	42)	Race						Black	 2835	(62)	 2076	(62)	 759	(63)						White	 975	(21)	 724	(21)	 251	(21)						Other	 772	(17)	 574	(17)	 198	(16)	Hispanic	Ethnicity	 443	(10)	 310	(9)	 133	(11)	Smoking	History		Current	 2372	(52)	 1685	(50)	 687	(57)						Former	 704	(15)	 550	(16)	 154	(13)						Never	 1506	(33)	 1139	(34)	 367	(30)	ART	Regimen						No	therapy	 ----	 1210	(36)	 ----						Monotherapy	 ----	 682	(20)	 ----						Combination		 ----	 635	(19)	 ----						HAART	 ----	 847	(25)	 ----	*25	patients	seroconverted	from	HIV-	to	HIV+	and	were	excluded
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3.2	Notation	Let	our	observed	data	be	represented	as	the	random	variable	𝑂! = 𝑍,𝐴,𝑌 !,	where	
Zc,	c	=	1	to	p,	are	the	p	components	of	the	covariate	vector	Z,	A	represents	the	exposure	of	interest	(in	both	aims,	HIV	serostatus)	with	possible	values	a	=	1	for	HIV	infected	women	and	a	=	0	for	HIV	uninfected	women,	and	Y	represents	an	outcome	variable.	For	Aim	1,	Y	represents	the	time	from	indication	to	initiation	of	a	statin.	In	Aim	2,	Y	represents	a	continuous	outcome	variable,	change	in	LDL	cholesterol,	measured	in	mg/dL.	In	the	following	equations,	uppercase	letters	denote	random	variables,	while	lowercase	letters	denote	possible	realizations	of	variables,	or	constants.	
3.3	Statistical	Methods	for	Chapter	4	(Aim	1)	Here	I	address	in	greater	detail	statistical	analysis	methods	for	Aim	1.	The	focus	in	the	following	section	is	the	technical	details	and	assumptions	underlying	the	statistical	models	used	in	Aim	1.	
3.3.1	Methods	for	Survival	Analysis	We	used	the	complement	of	the	Kaplan-Meier	estimator	to	construct	cumulative	incidence	curves	for	statin	initiation	after	an	indication	for	their	use	(64).	The	Kaplan-Meier	estimator	of	the	survivor	function	𝑆 𝑡 	is	below,	where	dj	is	the	number	of	events	at	time	j,	and	nj	is	the	risk	set	at	time	j:	
𝑆 𝑡! = 1− 𝑑!𝑛!!!!!
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To	control	for	confounding	and	loss	to	follow	up,	we	applied	inverse	probability	weights	(described	in	the	following	section).	From	the	weighted	cumulative	incidence	curves,	we	estimated	one	year,	two	year,	and	five	year	weighted	risk	differences	and	risk	ratios.	We	used	the	non-parametric	bootstrap,	with	200	resamples	with	replacement,	to	build	95%	confidence	intervals	for	both	risk	difference	and	risk	ratios.	(65).	We	estimated	hazard	ratios	and	95%	confidence	intervals	using	Cox	proportional	hazards	regression,	weighted	by	the	inverse	probability	weights.		
3.3.2	Inverse	Probability	Weights	Our	IP	weighted	Cox	proportional	hazards	model	is	fit	by	maximizing	the	following	weighted	partial	likelihood:	
𝐿 𝛽 = 𝑌! 𝑡 exp 𝛽𝐴!𝑌! 𝑡 exp 𝛽𝐴!!∈! ! !! !!!!!	We	used	inverse	probability	weights	to	control	for	confounding	and	loss	to	follow	up.	The	stabilized	weights	𝑊!" 𝑡 	can	be	expressed	as	the	product	of	a	time-fixed	weight	for	exposure	WA,	and	a	time-varying	weight	for	drop	out	𝑊! 𝑡 .	The	denominator	for	the	exposure	weights	𝑊!	are	estimated	from	a	logistic	regression	model	𝑃 𝐴 = 1 = expit 𝛽! + 𝛽!!!!! 𝑍!!! ,	and	the	numerator	for	the	exposure	weights	can	be	estimated	from	an	intercept-only	logistic	regression	model.	We	estimate	drop	out	weights	using	quintiles	of	the	observed	drop	out	time	distribution.	The	denominator	for	the	drop	out	weights	𝑊!	is	estimated	via	a	pooled	logistic	regression	model:	
𝑃 𝐷 𝑡 = 1 = expit 𝛽! 𝑡 + 𝛽!!!!! 𝑍! 𝑡
21
We	used	restricted	cubic	splines,	with	knots	at	the	5th,	35th,	65th,	and	95th	percentiles,	in	order	to	maintain	flexibility	in	modeling	continuous	variables	(66).	Efron’s	method	was	used	for	handling	event	ties	(67).		
3.4	Statistical	Methods	for	Chapter	5	(Aim	2)	
3.4.1	Estimate	of	Interest	In	Aim	2	we	estimated	changes	in	lipids	from	the	first	reported	use	of	a	statin	to	one	year	after.	Our	exposure	of	interest	was	HIV	serostatus,	a	binary	exposure,	and	the	primary	outcome	was	the	change	in	LDL	cholesterol.	We	also	looked	at	the	one	year	change	in	other	lipids,	such	as	HDL	cholesterol,	total	cholesterol,	and	triglycerides.	All	lipids	were	measured	in	mg/dL.	We	transformed	triglycerides	on	the	log10	scale	to	account	for	non-normality	of	that	particular	lipid.	
3.4.2	Linear	Regression	We	estimated	the	change	in	LDL	cholesterol	by	HIV	serostatus	using	a	linear	regression	model	estimated	via	maximum	likelihood,	with	a	normal	distribution	and	an	identity	link:	
𝐸 𝑌 = 𝛽! + 𝛽!𝐴 + 𝛽!!!!! 𝑍!!!	
3.4.3	Targeted	Maximum	Likelihood	Estimation	Our	implemention	of	the	TMLE	can	be	split	into	two	distinct	steps:	initial	estimation	of	the	outcome	using	the	SuperLearner	algorithm,	and	a	targeting	step	to	reduce	mean	squared	error	from	the	initial	estimate.	Note	that	SuperLearner	is	not	required	to	implement	TMLE;	the	initial	estimation	of	the	outcome	can	be	done	using	a	parametric	
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regression	estimator,	for	example.	Under	assumptions	of	treatment	variation	irrelevance	(68),	no	interference	(69),	positivity,	and	exchangeability	(62,70),	the	TMLE	produces	causal	estimates	that	are	targeted	to	the	parameter	of	interest	(59-60).	Suppose	we	have	a	dataset	with	n	observations,	with	complete	data	on	Y,	A,	and	Z.	We	wish	to	estimate	the	marginal	risk	of	the	exposure	A	on	the	outcome	Y,	controlling	for	the	covariates	Z1,	Z2,	and	Z3.	Specifically,	we	will	estimate	the	following	risk	ratio	Ψ:	Ψ = 𝐸!,! 𝐸! 𝑌|𝐴 = 1,𝑍  / 𝐸! 𝑌|𝐴 = 0,𝑍 	The	SuperLearner	produces	an	initial	(untargeted)	estimate	of	Q0,	or	the	probability	of	the	outcome	given	exposure	and	covariates,	using	cross-validation	of	several	different	algorithms.	The	steps	involved	in	the	SuperLearner	are	as	follows:	
1. Split	the	sample	into	V	separate	blocks.2. Fit	each	algorithm	to	V-1	of	the	blocks	(the	“training	set”).3. Using	the	coefficients	generated	from	the	training	set	fit	and	the	remaining	block(the	“validation	set”),	output	predicted	probabilities	for	each	algorithm.	The	vector
D	contains	the	set	of	predicted	probabilities	for	each	algorithm.4. Repeat	Steps	2	and	3	with	each	fold	as	the	validation	set.5. Calculate	the	cross-validated	mean	squared	error	for	each	algorithm:
𝐶𝑉 𝑀𝑆𝐸 = 𝑌! − 𝐷! !!!!! 𝑛6. Fit	a	logistic	regression	of	the	outcome	Y	on	the	set	of	predicted	probabilities	D.	Thecoefficients	generated	from	the	maximum	likelihood	estimate	of	this	regression	areincluded	in	the	SuperLearner	prediction	function.
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7. Iterate	this	procedure	for	both	levels	of	exposure	(A=1	and	A=0).
From	the	SuperLearner	prediction	function,	we	generate	an	initial	estimate	of	the	probability	of	the	outcome,	given	the	exposure	and	covariates.	The	second	step	targets	this	initial	estimate	to	reduce	bias	and	variance	for	the	targeted	parameter	of	interest.	It	does	this	through	the	use	of	a	“clever	covariate”,	which	includes	information	from	a	model	for	the	probability	of	exposure,	given	a	set	of	covariates.	This	step	includes	the	following:	
1. Fit	a	model	for	the	probability	of	the	exposure	A,	given	covariates	Z.	As	with	theinitial	estimate	of	the	outcome,	SuperLearner	may	be	used	to	fit	this	exposuremodel.2. From	the	results	of	this	exposure	regression,	create	a	covariate	designed	to	fluctuatethe	initial	outcome	estimate	Q0	to	minimize	bias	and	variance	for	the	targetedparameter.	This	covariate	is	often	called	a	“clever	covariate”	and	is	indexed	by	thefollowing	equation,	with	I(·)	an	indicator	function	of	exposure	and	g(·)	theprobability	of	exposure:
𝐻 𝐴,𝑍 ≡  𝐼(𝐴 = 1)𝑔 1  𝑍) −  𝐼(𝐴 = 0)𝑔 0  𝑍)3. Run	a	logistic	regression	of	the	outcome	Y	on	the	clever	covariate,	with	the	logit	ofthe	Q0	estimate	used	as	an	offset,	to	obtain	an	estimate	of	the	coefficient	ε	(theregression	coefficient	for	the	clever	covariate).
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4. Use	this	coefficient	ε	to	update	the	initial	estimate	of	Q0	to	an	updated	estimate,	Q1.Iterate	this	process	until	the	coefficient	ε	converges	to	0,	resulting	in	the	targetedestimate	QTMLE.	Note	that	QTMLE	is	calculated	for	each	observation	in	the	data	set.5. Repeat	Steps	3	and	4	for	A=1	and	A=0,	resulting	in	values	of	QTMLE	for	both	exposurelevels.	Risk	differences	and	ratios,	denoted	by	𝜓!"#$,	can	be	calculated	from	thesevalues.6. To	generate	estimates	of	precision,	calculate	the	influence	curve	(IC):
𝐼𝐶 =  𝐼 𝐴! = 1𝑔 1 | 𝑊! −  𝐼 𝐴! = 0𝑔 0 | 𝑊! 𝑌 −  𝑄!"#$ 𝐴!,𝑊!  +  𝑄!"#$ 1,𝑊! − 𝑄!"#$ 0,𝑊!−  𝜓!"#$	7. From	the	influence	curve,	a	sample	variance	can	be	calculated,	allowingconstruction	of	confidence	intervals	and	p-values:
𝑉𝑎𝑟 𝐼𝐶 =  1𝑛 𝐼𝐶! −  𝐼𝐶 !!!!! 	
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CHAPTER	4:	SIMILAR	USE	OF	STATINS	IN	HIV-INFECTED	AND	UNINFECTED	WOMEN	
IN	THE	WOMEN’S	INTERAGENCY	HIV	STUDY	
4.1	Introduction	The	management	of	HIV	has	shifted	in	part	from	the	prevention	and	treatment	of	opportunistic	illnesses,	to	establishing	and	maintaining	effective	antiretroviral	therapy	(ART),	and	to	the	prevention	and	treatment	of	non-HIV-associated	diseases	associated	with	aging	(4-5,	8-17,	35-36,	71-74).	Such	non-HIV	associated	conditions	are	emerging	as	the	leading	causes	of	mortality	among	persons	living	with	HIV,	and	among	these,	cardiovascular	disease	(CVD)	has	become	a	major	health	threat	(4-5,	35-40,	71-74).	A	cornerstone	of	CVD	prevention	is	the	reduction	in	atherogenic	lipids,	chiefly	LDL	cholesterol,	and	the	most	efficacious	and	potent	LDL-reducing	therapies	are	HMG-reductase	inhibitors	(i.e.,	statins)	(6).	While	use	of	statins	by	HIV-infected	patients	has	increased	(75-78),	it	remains	unclear	if	these	medications	are	prescribed	equally	to	those	with	and	without	HIV	infection,	particularly	women,	when	indicated.	It	has	been	reported	that	HIV-infected	patients	are	under-prescribed	preventive	care	including	statin	therapy	and	aspirin	for	CVD	prevention	(79-80),	but	published	studies	have	included	relatively	few	women.	To	what	extent	HIV-infected	women	experience	barriers	to	preventative	care	for	CVD	is	not	well	understood.	Using	data	on	4607	women	followed	with	semiannual	visits	for	up	to	14	years	in	the	Women’s	Interagency	HIV	Study	(WIHS),	we	evaluated	the	effect	of	HIV	infection	on	the	
26
uptake	of	statins	among	women	with	a	statin	indication.	We	also	explored	the	impact	of	the	recent	changes	in	national	guidelines	for	statin	initiation	among	HIV	infected	women	in	this	population	(6).	
4.2	Methods	
4.2.1	Women’s	Interagency	HIV	Study	The	Women’s	Interagency	HIV	Study	is	a	multicenter,	prospective	cohort	of	women	with	HIV	infection,	and	HIV-uninfected	controls	(58).	Based	in	multiple	urban	sites	across	the	United	States,	the	WIHS	began	recruitment	of	women	in	1994.	WIHS	women	complete	semiannual	study	visits,	including	an	extensive	interview	for	medication	history,	behavioral	risk	factors,	and	HIV-related	outcomes.	As	part	of	a	detailed	medication	history,	WIHS	women	are	asked	to	bring	in	all	their	prescribed	medications,	including	concomitant	medications	such	as	statins,	as	well	as	report	on	all	medications	used	since	their	last	semiannual	study	visit.	Blood	is	drawn	for	HIV	and	non-HIV	related	lab	values,	including	LDL	cholesterol	beginning	in	2000.	Our	study	period	includes	WIHS	participants	between	2000	and	2014.	
4.2.2	Statin	Guidelines	The	population	of	interest	comprised	women	without	prior	statin	use	who	were	followed	for	at	least	one	year	between	October	2000	and	December	2014,	and	who	had	an	indication	for	the	use	of	statin	therapy.	Our	primary	study	sample	included	WIHS	women	with	an	indication	for	statins	using	the	National	Cholesterol	Education	Program’s	Adult	Treatment	Panel	(ATP)	III	guidelines,	and	who	had	no	prior	reported	history	of	statin	use.	
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Published	in	2001	and	last	updated	in	2004,	the	ATP	III	guidelines	focused	on	risk	factors	for	coronary	heart	disease,	and	expanded	the	indication	for	statin	initiation	to	lower	LDL	cholesterol	values.	The	ATP	III	guidelines	for	statin	initiation	vary	based	upon	the	presence	of	coronary	heart	disease	or	other	atherosclerotic	disease,	diabetes,	the	Framingham	10-year	risk	score,	and	the	current	LDL	cholesterol	value.	In	2013	a	new	set	of	guidelines	for	statin	initiation	was	proposed	by	the	American	College	of	Cardiology	and	the	American	Heart	Association	(ACC/AHA)	(7).	These	new	guidelines,	which	further	expand	the	indication	for	statin	initiation	from	ATP	III,	have	met	with	controversy	(26).	We	used	the	ATP	III	guidelines	to	identify	WIHS	women	with	an	indication	for	statin	initiation,	as	they	were	the	guidelines	in	use	for	the	majority	of	the	study	period.	However,	we	also	used	the	2013	ACC/AHA	guidelines	to	estimate	the	number	of	women	who	would	have	had	an	indication	for	statins	if	the	2013	guidelines	had	been	in	place	during	the	study	period.	
4.2.3	Exposure,	Outcome,	and	Cohort	Our	outcome	of	interest	was	the	time	to	initiation	of	a	statin	after	an	indication	according	to	ATP	III	guidelines.	The	exposure	was	HIV	serostatus,	measured	at	each	WIHS	visit	for	HIV-uninfected	participants.	From	4607	women	in	the	WIHS	cohort,	we	excluded	885	women	who	died	or	were	lost	to	follow	up	prior	to	the	start	of	the	follow	up	period	in	October	2000.	269	women	were	missing	information	on	total	cholesterol,	HDL	cholesterol,	LDL	cholesterol,	diabetes	status,	or	insurance	status	and	were	excluded,	leaving	3,453	women.	We	then	determined	the	number	of	women	who	had	an	indication	for	statin	initiation	using	the	ATP	III	guidelines;	581	had	at	least	one	indication.	We	excluded	26	women	without	a	full	year	of	follow-up,	2	women	who	seroconverted	during	the	study,	and	
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80	women	who	used	a	statin	prior	to	their	indication.	The	final	cohort	for	analysis	included	473	women	with	an	indication	for	a	statin.	
4.2.4	Statistical	Methods	Among	women	for	whom	statin	therapy	is	indicated,	we	estimated	the	effect	of	HIV	serostatus	on	the	risk	of	statin	initiation.	We	adjusted	for	confounding	and	loss	to	follow	up	through	the	use	of	inverse	probability	weights,	including	weights	for	the	probability	of	exposure	and	the	probability	of	drop	out	(81).	The	final	weights	are	a	product	of	the	exposure	and	drop	out	weights.	We	included	age,	race,	education,	smoking,	hypertension,	baseline	total	cholesterol,	baseline	LDL	cholesterol,	baseline	HDL	cholesterol,	Framingham	10-year	risk	score,	and	insurance	status	as	covariates.	Cumulative	incidence	estimateswere	computed	over	the	time	since	the	statin	indication	(82).	We	used	Cox	proportional	hazards	regression	to	estimate	hazard	ratios	and	95%	confidence	intervals.	We	report	unadjusted	models	and	models	using	inverse	probability	weights	to	account	for	baseline	(measured	at	the	indication)	covariates	and	drop	out	from	the	cohort	(82).	We	report	one	year,	two	year,	and	five	year	risk	differences	and	risk	ratios	using	the	inverse-probability	weighted	cumulative	mortality	curves,	and	generated	confidence	intervals	using	200	bootstrapped	resamples.	To	maintain	flexibility	in	modeling	non-linear	effects	of	continuous	variables,	we	used	restricted	quadratic	splines,	with	knots	at	the	5th,	35th,	65th,	and	95th	percentiles	of	the	distribution	(83-84).	Treatment	effect	heterogeneity	by	the	Framingham	risk	score	was	explored	through	stratification	of	main	effects.	Analyses	used	SAS	Version	9.3	(Cary,	NC).	
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4.3	Results	Characteristics	for	473	women	with	an	indication	for	a	statin	are	shown	in	Table	1.	323	(68%)	of	the	women	in	our	cohort	were	HIV-infected.	Seropositive	women	were	older	on	average	and	more	likely	to	be	white.	Educational	attainment	was	similar	between	the	groups.	LDL	and	HDL	cholesterol	were	also	relatively	similar	between	the	two	groups.	The	median	LDL	cholesterol	among	HIV-infected	women	was	165	mg/dL;	among	HIV-uninfected	women,	it	was	160	mg/dL.	Most	(86%)	HIV-infected	women	used	ART,	the	median	CD4	cell	count	was	488,	and	the	median	log10	HIV	RNA	viral	load	was	2.3,	corresponding	to	an	undetectable	viral	load.			Five	years	after	an	indication,	38%	of	HIV-infected	women	reported	statin	use,	while	30%	of	HIV-uninfected	women	reported	use.	The	unadjusted	and	inverse	probability-weighted	results	for	the	effect	of	HIV	status	on	time	to	statin	initiation	after	an	indication	for	statins	are	presented	in	Table	2.	The	unadjusted	hazard	ratio	for	HIV-infected	women	compared	to	HIV-uninfected	women	was	1.37	(95%	CI:	0.95,	1.97).	After	accounting	for	imbalances	in	baseline	covariates	and	loss	to	follow	up,	we	observed	no	difference	in	the	uptake	of	statins,	with	a	weighted	hazard	ratio	of	0.95	(95%	CI:	0.63,	1.44).	The	weighted	one-year	risk	ratio	was	0.73	(0.18,	1.28),	and	the	two-year	risk	ratio	was	0.82	(0.39,	1.24).	We	also	stratified	by	categories	of	the	Framingham	risk	score	(<10,	>=10	units)	to	examine	heterogeneity	in	the	effect	of	HIV	on	receipt	of	a	statin.	We	again	found	little	difference	in	the	uptake	of	statins	among	HIV-infected	women	when	stratified	by	high	and	low	baseline	Framingham	risk	score,	although	our	results	were	limited	by	the	small	numbers	of	women	with	a	Framingham	score	of	at	least	10	at	baseline.	We	report	unadjusted	and	inverse	probability-weighted	cumulative	incidence	of	statin	initiation	
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curves	in	Figures	1	and	2.	While	in	the	unadjusted	curves	there	is	an	indication	of	an	increase	in	statin	initiation	for	HIV-infected	women,	in	comparison	to	HIV-uninfected	women,	the	weighted	curves	showed	no	difference	between	the	two	groups.		Applying	the	2013	ACC/AHA	guidelines	for	statin	initiation	to	our	population	more	than	doubled	the	number	of	women	with	an	indication	for	a	statin.	While	582	women	had	an	indication	with	the	ATP	III	guidelines	(including	women	with	less	than	a	year	of	follow-up	for	actually	initiating	a	statin),	1508	women	had	an	indication	with	the	ACC/AHA	guidelines.	The	prevalence	of	HIV	infected	women	indicated	for	statin	use	by	the	ATP	III	guidelines	was	16%,	and	increased	to	45%	with	the	ACC/AHA	guidelines.	Similar	trends	were	seen	among	HIV	uninfected	women.	Figure	4.3	displays	the	proportion	of	women	with	an	indication,	as	a	function	of	age,	when	applying	each	set	of	guidelines.	For	both	HIV-infected	and	negative	women,	the	ACC/AHA	guidelines	dramatically	increased	the	number	of	women	with	a	statin	indication.	 	
4.4	Discussion	Among	women	with	an	indication	for	statin	use,	we	observed	no	difference	in	the	uptake	of	statins	among	HIV-infected	women	compared	to	HIV-uninfected	women.	We	also	report	a	substantial	increase	in	the	proportion	of	women	with	a	statin	indication	when	applying	the	recent	2013	ACC/AHA	guidelines,	in	comparison	to	the	2001	ATP	III	guidelines,	with	both	HIV-infected	(16%	ATP	III	to	45%	ACC/AHA)	and	HIV-uninfected	(19%	to	42%)	women	in	our	cohort.	With	nearly	half	of	HIV	infected	women	in	our	cohort	now	having	an	indication	for	a	statin,	the	potential	consequences	of	greatly	expanding	statin	therapy	in	this	population	must	be	carefully	examined.	
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A	recent	report	by	Zanni	et	al.	highlighted	the	potential	for	the	2013	ACC/AHA	guidelines	to	underestimate	atherosclerotic	cardiovascular	disease	risk	in	HIV	infected	patients	(85).	Indeed,	while	they	found	a	2.5	fold	increase	in	the	proportion	of	patients	indicated	for	a	statin	when	applying	the	ACC/AHA	guidelines		versus	the	ATP	III	guidelines,	they	also	reported	that	74%	of	patients	with	high	risk	morphology	coronary	plaque	would	not	be	indicated	for	statin	use	in	their	cohort.	We	found	similar	results	in	a	national	multicenter	cohort;	the	increase	was	even	higher	(approximately	2.8	fold	increase)	in	HIV	infected	women	in	our	cohort.	Further	research	to	target	HIV	infected	groups	that	may	benefit	from	statin	therapy,	despite	the	lack	of	an	indication	by	current	guidelines,	is	needed.	Statin	use	has	continued	to	increase	in	the	general	US	population,	consistent	with	revised	guidelines	expanding	their	indications.	Using	data	from	the	National	Health	and	Nutrition	Examination	Survey	from	2005-2010,	the	proportion	of	US	adults	eligible	for	statin	treatment	rose	from	38%,	using	the	ATP	III	guidelines,	to	49%	with	the	ACC/AHA	guidelines	(27).	In	the	US	Medicare	population,	statin	use	rose	from	4%	in	1992,	to	41%	in	2008	(28).	In	HIV	infected	populations	in	the	US,	statin	use	is	also	increasing.	A	recent	cross-sectional	study	in	a	single	New	York	City	HIV	clinic	found	relatively	high	proportions	of	therapy	for	dyslipidemia	(including	alternative	options	such	as	fibrates,	fish	oil,	intestinal	inhibitors,	niacin,	and	bile	acid	sequestrants)	(90%)	and	hypertension	(75%)	among	HIV	infected	individuals	(29).	While	the	use	of	statins	in	our	population	is	lower	than	in	these	other	reports,	our	population	is	generally	younger	and	exposed	to	extensive	pharmacotherapy	for	their	HIV.		
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Risk	assessment	for	cardiovascular	disease	drives	much	of	the	use	of	statins,	but	in	the	setting	of	HIV,	there	is	also	increasing	interest	in	the	use	of	these	agents	for	their	potential	anti-inflammatory	properties	given	emerging	data	describing	heightened	immune	activation,	inflammation	(86),	and	rates	of	CVD	in	those	living	with	HIV	(4-5,	35-40,	71-74).	As	additional	evidence	for	their	benefits	accumulate,	it	can	be	expected	that	use	of	statins	in	HIV-infected	persons	will	grow.	While	the	potential	for	these	benefits	will	likely	continue	to	drive	increased	statin	use	in	HIV	infected	women,	treatment	decisions	must	also	take	into	account	the	possibility	of	reduced	adherence	to	ART	and	polypharmacy	in	an	aging	HIV	infected	population	(87-89).	Balancing	these	competing	considerations	will	be	essential	for	clinicians	deciding	on	treatment	plans	for	their	patients.	Our	finding	that	statin	indications	nearly	tripled	in	this	cohort,	while	expected	based	upon	the	guidelines,	reinforces	the	idea	that	future	studies	will	need	to	assess	the	uptake,	benefits,	and	potential	unintended	consequences	of	increased	statin	use	in	HIV	infected	women.		Our	study	has	limitations.	Statin	use	was	self-reported;	we	did	not	have	access	to	claims	data	to	verify	prescriptions,	or	biomarkers	to	verify	use.	It	is	likely	that	with	access	to	electronic	medical	records	or	prescription	claims	data,	our	incidence	of	new	statin	use	would	have	been	higher.	Additionally,	the	determination	of	an	indication	for	a	statin	requires	information	on	many	different	conditions,	including	smoking,	diabetes,	the	presence	of	coronary	heart	disease,	and	several	other	factors.	Misclassification	of	any	of	these	conditions	may	affect	the	construction	of	our	indication,	and	thus	our	analysis	cohort.	However,	because	any	one	condition	only	has	a	small	effect	on	determining	the	indication,	we	expect	this	issue	to	be	of	limited	importance.	Finally,	we	did	have	limited	precision	in	our	estimates	of	the	effect	of	HIV	status	on	statin	use	among	those	with	an	indication.	
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A	physician’s	choice	to	prescribe	a	statin	for	a	patient	is,	of	course,	informed	by	more	factors	than	a	simple	algorithm	provided	by	a	set	of	guidelines	(26).	In	many	cases,	the	ATP	III	guidelines	recommend	initiating	therapeutic	lifestyle	changes	prior	to	initiating	drug	therapy	(6).	Additionally,	physicians	may	be	reticent	to	add	additional	drugs	to	patients	who	may	already	be	taking	many	other	medications,	and	preferences	may	vary	widely	with	regards	to	how	aggressive	dyslipidemia	should	be	treated.		We	used	a	cohort	with	extensive	longitudinal	information	on	the	individual	conditions	and	lab	values	necessary	to	construct	an	indication	for	statin	initiation.	We	report	no	difference	in	the	uptake	of	statins	among	HIV-infected	women	in	comparison	to	HIV-uninfected	women.	We	also	report	a	substantial	increase	in	the	number	of	patients	with	an	indication	for	statin	initiation	as	a	result	of	the	2013	ACC/AHA	guidelines,	consistent	with	the	increases	found	in	the	general	US	population	(28).	As	the	HIV	population	continues	to	age	and	experiences	increased	cardiovascular	disease	risk,	further	research	on	the	use	of	pharmacotherapy	for	the	treatment	of	these	diseases,	and	the	consequences	of	their	interactions,	will	continue	to	be	of	importance.	
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TABLE	4.1:	Characteristics	of	women	at	the	indication	for	a	statin	Characteristic	 HIV-infected	(n	=	323)	 HIV-uninfected	(n	=	150)	Median	(IQR)	 No.	 %	 Median	(IQR)	 No.	 %	Age	 45	(39,	50)	 43	(35,	48)	Race						Black						White						Other	 188	83	52	 58	26	16	 92	23	35	 61	15	23	Education						<12	years						12	years	>12	years 111	96	116	 34	30	36	 55	47	48	 37	31	32	LDL	cholesterol	 165	(143,	190)	 160	(142,	178)	HDL	cholesterol	 45	(36,	55)	 46	(39,	55)	CD4	cell	count	 488	(326,	682)	Log10	HIV	RNA	 2.3	(2.3,	3.2)	ART	use	 277	 86	AIDS	diagnosis	 141	 44	Abbreviations:	HIV,	human	immunodeficiency	virus;	IQR,	interquartile	range;	No.,	number;	LDL,	low	density	lipoprotein;	HDL,	high	density	lipoprotein;	RNA,	ribonucleic	acid;	IQR,	interquartile	range;	ART,	antiretroviral	therapy;	AIDS,	acquired	immune	deficiency	syndrome	
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TABLE	4.2:	Effects	of	HIV	on	statin	initiation	among	women	with	an	indication	for	statin	use	
Indication	 Statin	
initiators	
Risk	 RD	(95%	CI)	 RR	(95%	CI)	 HR	(95%	CI)	
5	year	risk					Unadjusted									HIV-uninfected									HIV-infected	 150	323	 40	110	 0.30	0.38	 0	0.08	(-0.02,	0.18)	 1	1.27	(0.88,	1.66)	 1	1.37	(0.95,	1.97)					Weighteda										HIV-uninfected									HIV-infected	 151	328	 51	104	 0.38	0.37	 0	-0.01	(-0.14,	0.12) 1	0.98	(0.62,	1.34)	 1	0.95	(0.63,	1.44)	
2	year	risk					Unadjusted									HIV-uninfected									HIV-infected	 150	323	 23	56	 0.16	0.18	 0	0.02	(-0.05,	0.09)	 1	1.12	(0.65,	1.59)					Weighteda						HIV-uninfected									HIV-infected	 151	328	 29	52	 0.20	0.17	 0	-0.04	(-0.13,	0.06) 1	0.82	(0.39,	1.24)	
1	year	risk					Unadjusted									HIV-uninfected									HIV-infected	 150	323	 12	31	 0.08	0.10	 0	0.01	(-0.04,	0.07)	 1	1.17	(0.43,	1.91)					Weighteda											HIV-uninfected									HIV-infected	 151	328	 19	30	 0.13	0.09	 0	-0.03	(-0.11,	0.04) 1	0.73	(0.18,	1.28)	
Framingham	Risk	Scoreb	
<10					Unadjusted									HIV-uninfected									HIV-infected	 112	254	 27	87	 0.28	0.38	 0	0.10	(-0.01,	0.21)	 1	1.36	(0.85,	1.87)					Weighteda									HIV-uninfected									HIV-infected	 106	249	 31	79	 0.34	0.35	 0	0.01	(-0.14,	0.16)	 1	1.02	(0.55,	1.50)	
>=10					Unadjusted									HIV-uninfected									HIV-infected					Weighteda									HIV-uninfected									HIV-infected	
38	69	45	79	
13	23	20	25	
0.37	0.41	0.46	0.39	
0	0.04	(-0.17,	0.26)	0	-0.08	(-0.37,	0.22)
1	1.12	(0.40,	1.84)	1	0.84	(0.10,	1.58)	Abbreviations:	HIV,	human	immunodeficiency	virus;	RD,	risk	difference;	CI,	confidence	interval;	RR,	risk	ratio;	HR,	hazard	ratio	a	Weighted	results	are	adjusted	for	baseline	variables	recorded	at	the	first	visit	with	an	indication	for	a	statin,	and	include	age,	race,	smoking,	hypertension,	Framingham	Risk	Score	category	(<10	vs.	>=10),	insurance	status,	total	cholesterol,	HDL	cholesterol,	LDL	cholesterol,	and	education	b	Results	are	stratified	by	the	Framingham	Risk	Score	(<10	vs.	>=10)	at	the	initial	statin	indication.
FIGURE	4.1:	Unadjusted	cumulative	incidence	of	statin	initiation	after	an	indication	
for	statin	use	
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FIGURE	4.2:	Weighted	cumulative	incidence	of	statin	initiation	after	an	indication	for	
statin	use	
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FIGURE	4.3:	Statin	indication	by	age	and	changing	guidelines	
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CHAPTER	5:	MODIFICATION	OF	CHANGES	IN	LIPIDS	BY	HIV	STATUS	AMONG	
PATIENTS	TAKING	STATINS	IN	THE	WOMEN’S	INTERAGENCY	HIV	STUDY	
5.1	Introduction	HIV	clinicians	are	increasingly	confronted	with	metabolic	consequences	and	cardiovascular	sequelae	among	aging	HIV	patients	treated	with	antiretroviral	therapy	(ART)	(4-5,	35).	Hyperlipidemia	is	a	condition	that	might	result	from	the	effects	of	both	HIV	disease	and	ART	and	is	a	risk	factor	for	myocardial	infarction,	coronary	heart	disease,	and	other	cardiovascular	diseases	(8-17,	36).	Lipid	increases,	possibly	modified	by	ART,	may	require	the	addition	of	statins	to	a	comprehensive	treatment	plan	for	HIV	patients.	It	is	unclear	whether	HIV	affects	the	efficacy	of	statin	therapy	in	general,	and	specifically	the	drug’s	effects	on	lipid	levels.	Responses	to	statin	therapy	for	medication-	or	viral-associated	increases	in	cholesterol	and	triglycerides	may	not	be	as	robust	as	those	seen	in	dyslipidemia	among	HIV	uninfected	persons.	A	recent	analysis	found	that	HIV	infected	patients	had	a	smaller	reduction	(25.6%	vs.	28.3%)	in	LDL	cholesterol	than	patients	without	HIV	over	a	1	year	period	(30).	The	study,	however,	included	relatively	few	women	and	did	not	examine	outcomes	by	sex.	Interactions	between	ART	and	statins	have	been	well	characterized	(23).	Because	of	the	potential	for	dangerous	elevations	in	statin	concentrations	due	to	competitive	inhibition	of	the	enzyme	CYP3A4,	simvastatin	and	lovastatin	are	contraindicated	for	use	concomitantly	with	protease	inhibitors	(PI)	(23).	Additionally,	PI	have	been	associated	
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with	an	increased	incidence	of	hyperlipidemia	(90).	It	remains	unclear	whether	PI-mediated	increases	in	cholesterol	reduce	the	efficacy	of	statins,	in	comparison	to	HIV	patients	on	other	regimens.	We	estimated	the	effect	of	HIV	serostatus	on	the	1	year	change	in	lipid	values,	chiefly	LDL	cholesterol,	after	statin	initiation,	using	data	on	659	women	initiating	statin	therapy	in	the	Women’s	Interagency	HIV	Study	(WIHS)	between	2002	and	2014.	Among	those	infected	with	HIV,	we	estimated	the	effect	of	concomitant	protease	inhibitor	use	on	longitudinal	changes	in	LDL	cholesterol	and	other	lipid	parameters.	
5.2	Methods	
5.2.1	Women’s	Interagency	HIV	Study	We	used	data	from	the	WIHS,	a	longitudinal	observational	cohort	of	women	with	HIV-infected	and	HIV-uninfected	controls.	The	cohort	has	been	described	previously	(58,	91).	Briefly,	semiannual	visits	provide	information	on	key	measures	of	HIV	disease	history	and	progression.	Women	undergo	physical	examinations,	complete	interview	administered	questionnaires	on	a	wide	range	of	HIV	and	non-HIV	related	subjects,	and	give	blood	samples	for	laboratory	testing.	HIV-uninfected	women	are	tested	for	HIV	at	each	WIHS	visit.	Participants	bring	all	prescribed	medications,	including	concomitant	medications	such	as	statins,	as	well	as	report	on	all	medications	used	since	their	last	study	visit.	Our	study	sample	included	women	who	first	reported	use	of	a	statin,	after	at	least	two	study	visits	prior	to	the	statin	initiation.	We	used	a	new	user	cohort	design	(92-93),	which	limits	the	potential	for	prevalent	user	bias.	If	risk	varies	over	time,	this	bias	may	occur	because	prevalent	users	are	survivors	of	an	earlier	period	of	therapy.	
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5.2.2	Exposure	and	Outcome	Assessment	HIV	serostatus	is	the	exposure	of	interest,	measured	at	each	study	visit	for	HIV-uninfected	controls.	Our	outcome	was	the	change	in	LDL	cholesterol	from	baseline	(visit	prior	to	reporting	statin	use)	to	the	visit	following	their	first	report	of	statin	use,	which	was	approximately	one	year.	If	a	participant	did	not	have	an	LDL	cholesterol	value	at	the	follow-up	visit,	we	used	the	LDL	value	from	the	subsequent	visit.	We	limited	the	follow-up	period	to	a	maximum	of	two	visits	after	the	initial	reported	statin	use.	Because	participants	are	interviewed	on	their	use	of	statins	in	the	previous	six	months	from	the	visit	date,	statin	exposure	begins	in	the	six	month	period	prior	to	being	recorded	at	a	WIHS	visit.	As	a	result,	we	recorded	the	baseline	LDL	cholesterol	level,	as	well	as	any	baseline	confounders,	at	the	visit	prior	to	the	first	reported	use	of	a	statin.	We	did	not	measure	baseline	covariates	at	the	same	visit	as	the	initial	statin	report,	because	those	covariates	are	likely	to	be	affected	by	statin	exposure	in	the	six	months	before	the	visit.	
5.2.3	Statistical	Analysis	Let	our	observed	data	be	represented	as	𝑂! = 𝑊,𝐴,𝑌 ! ,	where	𝑊! , 𝑗 = 1 to 𝑝,	are	the	𝑝	components	of	the	covariate	vector	𝑊,	𝐴	represents	the	exposure	of	interest	(HIV	serostatus)	with	possible	values	𝑎 = 1	for	HIV-infected	women	and	𝑎 = 0	for	HIV-uninfected	women,	and	𝑌	represents	a	continuous	outcome	variable,	change	in	LDL	cholesterol,	measured	in	mg/dL.	Uppercase	letters	denote	random	variables,	while	lowercase	letters	denote	possible	realizations	of	variables,	or	constants.		
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We	fit	the	linear	regression	𝐸 𝑌 = 𝛽! + 𝛽!𝐴 + 𝛽!𝑊!!!!!!!!! ,	to	estimate	the	one	year	change	in	LDL	cholesterol.	As	a	second	modeling	approach,	we	used	targeted	maximum	likelihood	estimation	(TMLE)	with	super	learning.	TMLE	allows	the	estimation	of	causal	effects	under	the	assumptions	of	treatment-variation	irrelevance,	conditional	exchangeability,	and	positivity	(68,	94-95).	Unlike	a	Gaussian	model	estimated	using	maximum	likelihood,	TMLE	does	not	require	the	specification	of	a	correct	parametric	form	for	the	outcome	model.	Such	an	estimator	has	several	desirable	properties:	it	is	doubly	robust	(96),	can	leverage	a	diverse	collection	of	algorithms	in	addition	to	traditional	regression	models,	and	minimizes	bias	and	variance	for	the	particular	target	causal	quantity,	rather	than	potential	nuisance	parameters	such	as	confounders	(59-60).	TMLE	does	have	limitations:	it	is	computationally	intensive,	and	is	less	than	fully	parametrically	efficient.	However,	TMLE	is	semiparametrically	efficient	(meaning	this	estimator	is	a	maximally	efficient	member	of	the	set	of	regular	asymptotically	linear	semiparametric	estimators)	(59-60).	Appendix	1	includes	a	more	detailed	description	of	TMLE.	As	a	secondary	aim,	among	those	women	infected	with	HIV,	we	estimated	the	effect	of	a	concomitant	PI	regimen,	in	comparison	to	women	concomitantly	on	any	other	type	of	ART,	on	longitudinal	LDL	cholesterol	changes.	For	this	secondary	aim,	we	excluded	HIV-uninfected	women	and	those	HIV-infected	women	not	on	ART.	We	also	used	both	linear	regression	and	TMLE	for	this	secondary	aim.	To	appropriately	account	for	observations	with	missing	data,	we	used	an	inverse	probability	weighted	complete	case	analysis	approach.	Let	𝑅 = 1	indicate	a	complete	case	(i.e.	no	missing	data	for	all	relevant	variables	𝑊,	𝐴,	and	𝑌).	We	fit	a	model	for	the	logit	𝑃 𝑅 = 1|𝐴,𝑉 ,	where	logit	𝑝 =	log 𝑝/ 1− 𝑝 .	𝑉	is	the	subset	of	𝑊	with	completely	
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observed	data.	Inverse	probability	weights	𝑀	are	constructed	as	𝑀 = !" !!!!" !!!|!,! .	Analysis	included	all	subjects	where	𝑅 = 1,	weighted	by	𝑀.	While	statins	are	primarily	indicated	for	lowering	LDL	cholesterol,	they	do	have	effects	on	other	lipids	such	as	HDL	cholesterol,	total	cholesterol,	and	triglycerides.	We	examined	the	association	of	HIV	serostatus	on	the	one-year	change	in	these	other	lipids	among	new	statin	users.	We	included	the	following	covariates	in	our	primary	model	estimating	the	change	in	LDL	cholesterol:	age,	race,	smoking,	HDL	cholesterol,	total	cholesterol,	triglycerides,	an	indicator	of	high	statin	potency,	calendar	time,	and	insurance	status.	Women	taking	atorvastatin,	rosuvastatin,	or	simvastatin	were	defined	as	taking	a	high	potency	statin.	We	did	not	adjust	for	baseline	values	of	a	lipid	(i.e.	in	the	primary	analysis	of	LDL	cholesterol	change,	we	did	not	adjust	for	baseline	LDL	cholesterol)	(97).	For	estimating	the	effect	of	PI	regimens	on	LDL	cholesterol	changes	among	HIV-infected	women,	we	also	included	the	HIV	biomarkers	CD4	cell	count	and	HIV	RNA	viral	load.	Treatment	effect	heterogeneity	was	explored	through	stratification	by	baseline	smoking	status,	race,	and	calendar	time.	We	used	SAS	9.3	(Cary,	NC)	for	all	linear	regression	models,	and	R	3.2.1	(R	Foundation	for	Statistical	Computing,	Vienna,	Austria)	to	implement	TMLE.	
5.3	Results	Out	of	659	statin	initiators,	481	(73%)	were	HIV-infected	(Table	1).	Atorvastatin	was	the	most	commonly	used	statin	in	both	HIV-infected	and	HIV-uninfected	groups.	Pravastatin	use	was	more	prevalent	in	the	HIV-infected	group	(28%	vs.	11%),	while	simvastatin	use	was	less	prevalent	(9%	vs.	37%).	Age	and	education	were	similar	between	
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the	groups,	while	HIV-infected	women	were	more	likely	to	be	white	and	less	likely	to	be	current	smokers.	LDL	cholesterol	levels	were	slightly	higher	in	the	HIV-infected	group	(Median:	126	mg/dL	vs.	121),	and	triglyceride	levels	were	higher	(162	mg/dL	vs.	124).	ART	use	was	extensive	(94%),	and	53%	of	women	with	HIV	used	a	protease	inhibitor	as	part	of	their	ART	regimen.	The	median	time	between	the	measurement	of	the	baseline	and	follow-up	cholesterol	was	1.4	years.	We	had	complete	information	on	all	covariates	on	a	total	of	438	(66%)	women.	We	report	the	association	between	HIV	serostatus	and	lipid	changes	in	Table	2	and	Figure	1.	LDL	cholesterol	was	reduced	in	both	exposure	groups.	In	the	unadjusted	model,	the	mean	change	in	LDL	cholesterol	for	HIV-infected	women	was	-16.4	mg/dL	(95%	CI:	-90.5,	57.7);	in	HIV-uninfected	women,	it	was	-15.5	mg/dL	(95%	CI:	-94.9,	63.9).	Using	linear	regression,	the	adjusted	difference	in	mean	change	between	the	groups	was	3.3	mg/dL	(95%	CI:	-4.0,	10.6).	This	was	indicative	of	a	slightly	smaller	LDL	response	to	statins	among	HIV-infected	women	(i.e.	the	LDL	cholesterol	reduction	was	greater	in	magnitude	in	HIV-uninfected	women	than	in	HIV-infected	women).	We	found	similar	results	using	TMLE,	with	a	difference	in	mean	change	of	2.3	mg/dL	(95%	CI:	-5.4,	10.1).	Among	HIV-infected	women,	we	found	little	difference	in	mean	LDL	cholesterol	change	between	those	women	concomitantly	taking	a	PI	and	those	women	not.	The	adjusted	difference	in	mean	change	for	women	concomitantly	taking	a	PI,	compared	to	those	women	not	taking	a	PI,	was	0.8	mg/dL	(95%	CI:	-6.5,	8.0).	The	results	for	the	effect	of	HIV	serostatus	on	other	lipid	parameters,	including	HDL	cholesterol,	total	cholesterol,	and	triglycerides,	are	presented	in	Table	3.	Among	HIV	infected	women,	the	mean	change	in	HDL	cholesterol	was	1.9	mg/dL	(95%	CI:	-21.7,	25.6),	
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and	among	HIV	uninfected	women,	the	mean	change	was	-0.3	(95%	CI:	-26.9,	26.3).	The	adjusted	difference	in	mean	change	was	1.6	mg/dL	(95%	CI:	-1.0,	4.2).	For	total	cholesterol,	the	mean	change	among	HIV-infected	women	was	-21.5	mg/dL,	while	among	HIV-uninfected	women,	it	was	-15.9	mg/dL.	
5.4	Discussion	Using	a	linear	regression	model	and	a	targeted	maximum	likelihood	estimator,	we	found	a	small	difference	between	HIV-infected	women	and	HIV-uninfected	women	in	the	difference	in	mean	change	in	response	to	statin	therapy	after	one	year.	While	both	groups	of	women	experienced	reductions	in	their	LDL	cholesterol	after	initiating	a	statin,	the	adjusted	mean	reduction	was	greater	for	HIV-uninfected	women	(-17.4	mg/dL	vs.	-15.1	mg/dL).	There	was	an	indication	that	HDL	responses	were	slightly	improved	among	HIV-infected	women,	in	comparison	to	HIV-uninfected	women.	It	is	unclear,	however,	if	a	difference	of	approximately	2	mg/dL	in	HDL	cholesterol	is	clinically	significant.		Our	results	show	similar	associations	to	those	found	in	a	recent	Kaiser	Permanente	study	that	primarily	included	men	(30).	HIV-infected	women	had	slightly	less	robust	responses	to	statin	therapy	in	comparison	to	HIV-uninfected	patients.	However,	our	study	population	began	statin	therapy	at	much	lower	levels	of	LDL	cholesterol	(median	baseline	LDL	cholesterol:	124	mg/dL).	Reductions	as	a	proportion	of	the	baseline	LDL	cholesterol	were	generally	lower	than	in	the	general	population.	HIV-infected	women	had	a	mean	reduction	of	12%	from	baseline,	while	HIV-uninfected	women	had	a	reduction	of	16%.	This	contrasts	to	relative	reductions	in	the	general	population	of	30-63%	(98-104),	including	one	notable	trial	result	comparing	atorvastatin	vs.	rosuvastatin	in	an	African	American	
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cohort	that	found	reductions	in	LDL	cholesterol	ranging	from	32%	to	46%.	However,	the	participants	in	this	trial	had	very	high	baseline	LDL	cholesterol	values;	the	mean	baseline	value	was	approximately	190	mg/dL	for	each	study	arm.	Our	results	may	be	partially	explained	by	our	relatively	young	population	of	new	statin	users,	who	are	beginning	statin	therapy	at	lower	LDL	cholesterol	levels.		Our	study	has	limitations.	Our	LDL	changes	were	based	upon	a	single	lipid	measurement,	which	is	subject	to	measurement	error.	Further,	statin	use	is	self-reported	over	a	period	of	several	months,	and	we	lack	information	on	adherence	to	statin	therapy.	This	may	be	important	particularly	in	a	HIV-infected	population	concomitantly	taking	ART.	As	ART	is	indicated	in	this	population,	it	may	be	that	adherence	to	statins,	once	started,	is	less	than	optimal	in	comparison	to	the	general	population	not	subject	to	complex	ART	regimens.	However,	there	are	advantages	to	our	study	design.	The	WIHS	is	a	well-defined	interval	cohort	with	standardized	procedures.	We	have	extensive	information	on	potential	confounders,	and	used	modern	methods	to	account	for	confounding.		Our	results	suggest	that	dyslipidemia	among	HIV-infected	women	does	respond	to	statin	therapy.	Continuous	monitoring	of	cardiovascular	health	in	HIV-infected	women	is	warranted.	However,	we	did	not	find	a	dramatic	difference	in	LDL	cholesterol	response	to	statin	therapy	based	upon	HIV	serostatus.	
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TABLE	5.1:	Characteristics	of	new	statin	users	at	first	statin	initiation	Characteristic	 HIV-infected	(n	=	481)	 HIV-uninfected	(n	=	178)	Median	(IQR)	 No.	 %	 Median	(IQR)	 No.	 %	Statin:						Atorvastatin						Pravastatin						Simvastatin						Rosuvastatin						Lovastatin						Fluvastatin	
280	134	43	17	8	5	
58	28	9	4	2	1	
74	19	66	9	11	0	
42	11	37	5	6	0	Age	 47	(42,	53)	 49	(43,	54)	Race:						Black						White						Other	 274	119	88	 57	25	18	 125	23	30	 70	13	17	Smoking	 181	 38	 96	 54	Education:						<12	years						12	years	>12	years 182	133	165	 38	28	34	 69	50	59	 39	28	33	LDL	cholesterol	 126	(102,	153)	 121	(95,	153)	HDL	cholesterol	 46	(36,	60)	 48	(39,	63)	Total	cholesterol	 215	(183,	245)	 208	(172,	236)	Triglycerides	 162	(109,	248)	 124	(87,	186)	Any	insurance	 468	 97	 154	 87	CD4	cell	count	 565	(394,	776)	Log10	HIV	RNA	 2.3	(2.3,	2.5)	ART	use	 453	 94	AIDS	diagnosis	 205	 43	PI	use	 257	 53	Abbreviations:	 IQR,	 interquartile	 range;	 LDL,	 low	 density	 lipoprotein;	 HDL,	 high	 density	lipoprotein;	ART,	antiretroviral	therapy;	PI,	protease	inhibitor	
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TABLE	5.2:	Effects	of	HIV	and	PI	use	on	LDL	cholesterol	changes	among	women	who	
initiate	a	statin	 Mean	change	in	LDL	(SD)	 Difference	in	mean	change	(95%	CI)	Effect	of	HIV	among	all	statin	users					Unadjusted									HIV-uninfected									HIV-infected	 -15.5	(40.5)-16.4	(37.8) 0	-0.9	(-9.1,	7.3)				Adjusteda									HIV-uninfected									HIV-infected	 0	3.3	(-4.0,	10.6)					TMLEa									HIV-uninfected									HIV-infected	 -17.4	(17.6)-15.1	(17.6) 0	2.3	(-5.4,	10.1)	Effect	of	concomitant	PI	use	among	HIV-positive					Unadjusted									No	PI									PI	 -16.1	(31.5)	-16.5	(41.8)	 0	-0.4	(-8.8,	7.9)				Adjustedb									No	PI									PI	 0	0.8	(-6.5,	8.0)					TMLEb									No	PI									PI	 -16.9	(17.2)	-16.0	(17.2)	 0	0.8	(-4.4,	6.0)	Abbreviations:	SD,	standard	deviation;	CI,	confidence	interval;	TMLE,	targeted	maximum	likelihood	estimation	a	Adjusted	for	age,	race,	smoking,	baseline	total	cholesterol,	baseline	HDL	cholesterol,	baseline	log10	triglycerides,	statin	potency,	and	calendar	year	b	Adjusted	for	age,	race,	smoking,	baseline	total	cholesterol,	baseline	HDL	cholesterol,	baseline	log10	triglyderides,	statin	potency,	calendar	year,	baseline	CD4	count,	and	baseline	HIV	RNA	
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TABLE	5.3:	Effects	of	HIV	on	other	lipid	changes	among	women	who	initiate	a	statin	
Mean	change	in	lipid	
(SD)	
Difference	in	mean	change	
(95%	CI)	HDL	cholesterol					Unadjusted									HIV-uninfected									HIV-infected	 -0.3	(13.6)1.9	(12.1) 0	2.2	(-0.4,	4.9)					Adjusteda									HIV-uninfected									HIV-infected																	TMLE									HIV-uninfected									HIV-infected	Total	cholesterol					Unadjusted									HIV-uninfected									HIV-infected					Adjusted									HIV-uninfected									HIV-infected					TMLE									HIV-uninfected									HIV-infected		
-0.5	(4.2)1.9	(4.2)
-15.9	(45.5)-21.5	(45.7)
-19.4	(25.0)-20.2	(25.1)
0	1.6	(-1.0,	4.2)	0	2.4	(0.2,	4.6)	
0	-5.6	(-15.4,	4.1)0	2.7	(-5.6,	11.0)	0	-0.8	(-8.3,	6.6)Log10	Triglycerides					Unadjusted								HIV-uninfected	 0.01	(0.18)	 0									HIV-infected	 -0.05	(0.22) -0.06	(-0.10,	-0.01)				Adjusted									HIV-uninfected	 0									HIV-infected	 -0.02	(-0.06,	0.02)				TMLE									HIV-uninfected	 0.11	(0.04)	 0									HIV-infected	 0.06	(0.05)	 -0.05	(-0.10,	0.00)SD,	standard	deviation;	CI,	confidence	interval;	PI,	protease	inhibitor	a	Adjusted	for	age,	race,	smoking,	baseline	total	cholesterol,	baseline	HDL	cholesterol,	baseline	log10	triglycerides,	statin	potency,	and	calendar	year	b	Adjusted	for	age,	race,	smoking,	baseline	LDL	cholesterol,	baseline	HDL	cholesterol,	baseline	log10	triglycerides,	statin	potency,	and	calendar	year	c	Adjusted	for	age,	race,	smoking,	baseline	LDL	cholesterol,	baseline	HDL	cholesterol,	baseline	total	cholesterol,	statin	potency,	and	calendar	year	
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FIGURE	5.1:	Lipid	changes	by	HIV	serostatus	approximately	one	year	after	statin	
initiation	
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CHAPTER	6:	DISCUSSION	
6.1	Summary	Our	objective	in	this	work	was	to	explore	the	usage	and	effects	of	statins	in	a	population	of	HIV	infected	women	in	the	United	States.	In	an	environment	of	increasingly	aggressive	guidelines	for	treatment,	and	evidence	that	statins	may	have	multiple	effects	on	this	particular	population,	including	lipid	lowering	and	anti-inflammatory	benefits,	it	is	important	to	look	at	patterns	of	usage	and	the	effectiveness	of	these	medications.		In	Aim	1,	we	found	no	evidence	of	differential	statin	uptake	by	HIV	serostatus	after	an	indication	for	their	use.	We	had	hypothesized	that	HIV	infected	patients	would	be	less	likely	to	receive	statins	when	indicated.	This	hypothesis	was	motivated	by	the	potential	for	polypharmacy	in	an	already	extensively	treated	population,	as	well	as	concern	regarding	coordination	of	care	between	HIV	physicians	and	cardiovascular	disease	specialists.	We	speculated	that	HIV	physicians,	who	are	usually	the	primary	point	of	health	care	for	this	population,	may	be	less	likely	to	aggressively	treat	this	particular	comorbidity	(or	indeed,	other	comorbidities	in	general)	due	to	concerns	about	adherence	to	antiretroviral	therapy.	Our	findings	support	the	conclusion	that	HIV	infected	women	are	not	less	likely	than	HIV	uninfected	women	to	receive	statin	therapy	when	indicated.		We	examined	the	differential	effects	of	statin	therapy	by	HIV	serostatus	in	Aim	2.	Silverberg	et	al.	(30)	showed	previously,	in	a	cohort	of	primarily	men,	that	statins	were	
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slightly	less	effective	in	HIV	infected	patients	than	HIV	uninfected	patients.	These	results	motivated	our	current	analysis,	as	we	wished	to	explore	a	similar	analysis	in	women.	Although	we	were	somewhat	limited	by	a	lack	of	precision,	we	found	that	HIV	infected	women	in	the	WIHS	had	smaller	reductions	in	their	LDL	cholesterol	one	year	after	initiation	of	therapy	than	did	HIV	uninfected	women.	From	an	epidemiologic	methods	perspective,	we	also	implemented	a	relatively	new	technique	for	causal	inference,	targeted	maximum	likelihood	estimation.	Under	an	appropriate	set	of	identifiability	assumptions	(namely,	treatment	variation	irrelevance,	no	interference,	exchangeability,	positivity,	no	exchangeability,	and	correct	models	specification),	TMLE	allows	semi-parametric	estimation	of	causal	effects	using	a	broad	library	of	both	traditional	parametric	regression	models,	as	well	as	non-parametric	estimators	such	as	random	forest	or	neural	networks.	This	class	of	estimators	has	been	shown	to	have	some	desirable	properties,	in	particular,	minimizing	mean-squared	error	for	a	targeted	parameter	of	interest.	Applications	in	the	epidemiologic	literature	have	been	limited	to	date;	we	hope	our	use	of	these	methods	will	bring	further	exposure	to	their	utility	and	potential	benefits	to	their	use	for	epidemiologists.	
6.2	Limitations	The	interval	nature	of	the	WIHS	cohort	results	in	a	limitation	to	our	design	and	inferences.	While	we	do	have	information	at	appoximately	six	month	intervals	on	behavioral	characteristics,	such	as	smoking	and	alcohol	abuse,	and	clinically	relevant	laboratory	values,	such	as	CD4	cell	count	and	HIV	RNA	viral	load,	we	lack	pharmacy	claims	data	on	the	use	of	medications	such	as	ART	and	statins.	While	the	use	of	these	medications	
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is	specifically	asked	as	part	of	the	WIHS	interview,	they	only	give	us	information	on	medication	use	during	the	full	interval.	We	cannot	confirm	the	exact	dates	of	medication	prescriptions,	which	would	be	beneficial	in	a	time-to-event	analysis.	One	of	the	primary	limitations	of	Aim	1	is	the	number	of	variables	that	are	required	to	determine	whether	a	woman	has	an	indication	for	a	statin.	Measurement	error	in	one	or	more	of	these	variables	could	theoretically	compound	across	the	calculation	of	the	indication.	However,	it	could	also	be	argued	that	error	in	a	single	variable	would	not	unduly	affect	the	full	calculation.	Moreover,	most	of	the	variables	used	to	determine	an	indication	(age,	smoking	status,	presence	of	diabetes,	etc.)	are	measured	at	every	WIHS	visit	and	we	have	a	relatively	high	degree	of	confidence	in	their	measurement.	Ideally,	we	could	measure	the	exact	date	of	the	initial	statin	prescription	using	claims	data.	Finally,	with	only	473	women	with	an	indication	who	had	not	previously	reported	use	of	a	statin,	the	precision	in	our	estimates	was	limited.	As	the	primary	outcome	measured	in	Aim	2	was	a	change	in	LDL	cholesterol	measured	over	one	year	after	statin	initiation,	we	would	have	preferred	having	multiple	measurements	of	LDL	cholesterol.	The	reliability	of	a	single	measurement	may	be	questionable,	but	we	were	limited	by	the	interval	nature	of	the	data.	Further,	in	some	cases	we	lacked	data	on	follow-up	lipids	at	the	visit	following	the	intial	report	of	statin	use.	In	these	cases,	we	used	the	lipid	value	at	the	second	visit	after	the	initial	statin	report.	As	a	result	it	is	somewhat	difficult	to	determine	the	time	period	over	which	our	estimates	are	valid.	Finally,	fasting	lipids	would	have	been	preferable,	but	we	only	had	access	to	random	lipid	values.	
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As	with	all	observational	studies,	unmeasured	confounding	is	a	limitation.	While	the	WIHS	interview	provides	a	detailed,	rich	set	of	information,	there	are	certainly	unmeasured	characteristics	of	our	cohort	that	may	bias	the	effects	of	interest	in	our	two	aims.	For	example,	in	Aim	1,	more	granular	measurement	of	access	to	care,	particularly	cardiovascular	specialty	care,	may	confound	the	association	between	HIV	serostatus	and	statin	use.	Another	issue	that	may	affect	the	validity	of	our	estimates	is	selection	bias	(105).	In	order	to	be	eligible	for	inclusion	in	our	cohort	for	Aim	1,	women	needed	to	have	information	available	on	several	different	variables	(smoking	status,	hypertension	status,	diabetes	status,	etc.)	to	construct	an	indication	for	a	statin.	Our	effect	estimate	may	be	biased	if	the	availability	of	these	variables	differed	by	HIV	serostatus.	In	Aim	2,	inclusion	into	the	cohort	was	contingent	on	the	availability	of	baseline	and	follow-up	lipids.	While	our	definition	of	the	follow-up	period	mitigated	some	of	these	concerns	(we	allowed	the	follow-up	lipid	from	either	of	two	successive	follow-up	visits	to	be	used),	there	were	patients	without	available	lipid	values	at	either	baseline	or	follow-up	who	were	not	included	in	the	analysis	cohort.		Finally,	the	external	validity	of	our	estimates	may	be	questionable.	The	WIHS	is	very	distinct	population,	with	oversampling	of	blacks,	Hispanics,	and	uninfected	controls	matched	on	demographics	and	behavioral	characteristics,	such	as	injection	drug	use	and	total	number	of	sexual	partners.	As	such,	it	is	likely	not	possible	to	directly	generalize	these	estimates	to	larger	target	populations	of	interest,	such	as	the	population	of	all	HIV	infected	women	in	the	United	States.	While	not	included	in	this	work,	new	methods	for	the	generalizability	and	transportability	of	estimates	to	other	target	populations	using	inverse	probability	weighting	are	in	development.		
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6.3	Strengths	The	primary	strengths	of	this	work	lie	in	the	quality,	diversity,	and	longitudinal	nature	of	the	data	available	through	the	WIHS	cohort.	We	have	excellent,	repeated	measurements	of	HIV-related	laboratory	data,	as	well	as	very	thorough	information	on	behavioral	characteristics	such	as	smoking	and	alcohol	abuse.	Additionally,	we	have	excellent	information	on	medication	use,	including	both	ART	and	statins.	Many	clinical	cohorts	have	excellent	information	on	clinically	relevant	diagnoses	and	laboratory	values,	while	perhaps	less	complete	information	on	behaviors.	The	WIHS	combines	extensive,	longitudinal	information	on	HIV-related	diagnoses,	antiretroviral	therapy,	behaviors,	laboratory	values,	and	concomitant	medications	to	provide	a	detailed	history	of	the	progression	of	disease	in	HIV	infected	controls.	Additionally,	the	availability	of	HIV	uninfected	controls	allows	for	effects	of	HIV	itself	to	be	investigated.	We	used	modern	statistical	methods	to	acccount	for	confounding,	selection	bias,	loss	to	follow	up,	and	missing	data.	In	Aim	1,	we	used	a	weighted	Cox	proportional	hazards	regression	model	to	consistently	estimate	hazard	ratios	and	95%	confidence	intervals.	Using	inverse	probability	of	exposure	and	drop	out	weights	allowed	us	to	both	control	for	measured	confounding	and	loss	to	follow	up,	while	at	the	same	time	giving	us	a	marginal	effect	estimate.	In	Aim	2,	in	addition	to	the	standard	method	of	maximum	likelihood	estimation	of	a	linear	regression	model,	we	also	implemented	TMLE.	This	estimator	has	good	variance	properties	and	allows	the	estimation	of	causal	effects	with	a	diverse	collection	of	both	parametric	and	non-parametric	algorithms.		Finally,	we	contribute	evidence	to	an	area	of	research	that	is	growing	in	importance	for	HIV	infected	women:	the	effect	of	HIV	on	long-term	cardiovascular	health.	As	
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indications	for	statin	therapy	expand,	it	is	important	to	continue	to	measure	the	uptake	and	efficacy	of	statins	in	this	vulnerable	population.	Consistent	with	an	aging	HIV	infected	population	and	evidence	for	potential	benefits	beyond	LDL	cholesterol	control	(86),	it	is	virtually	certain	that	statin	use	will	increase.	Our	study	addressed	important	questions	related	to	access	to	statins	for	HIV	infected	women,	in	comparison	to	HIV	uninfected	women.	We	quantified	how	changing	guidelines	will	dramatically	increase	the	proportion	of	HIV	infected	women	in	the	WIHS	who	are	indicated	for	statin	therapy.	Additionally,	we	examined	the	efficacy	of	statin	therapy	by	HIV	serostatus,	as	previous	work	primarily	in	men	(30)	indicated	a	slightly	reduced	benefit	for	HIV	infected	women.	
6.4	Future	Directions	for	Research	and	Policy	To	date	there	is	limited	information	on	trends	in	usage	and	the	efficacy	of	statins	in	HIV	infected	patients,	particularly	among	women.	Additional	research	describing	the	use	of	statins	in	women	infected	with	HIV,	possibly	in	older	cohorts	of	patients	in	which	indications	may	be	more	likely,	is	warranted.	Indeed,	statin	users	in	our	cohort	(median	age:	48)	were	generally	younger	than	in	many	typical	cohorts	in	the	general	population	(98-104).	The	HIV	infected	population	is	aging,	and	such	investigations	of	trends	in	statin	use	may	be	more	feasible	as	more	women	are	indicated	for	statin	use	over	time.		The	application	of	guidelines	advocating	for	more	aggressive	statin	therapy	requires	monitoring	in	this	population.	As	the	2013	ACC/AHA	recommendations	have	not	been	met	with	universal	approval	(26),	it	may	take	a	longer	period	of	time	for	treatment	trends	to	reflect	the	new	recommendations.	This	may	particularly	be	the	case	in	the	HIV	infected	population,	as	clinicians	may	be	more	likely	to	be	hesitant	about	using	a	more	aggressive	
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treatment	posture.	HIV	patients	already	are	on	extensive	pharmacotherapy,	and	due	to	concerns	regarding	polypharmacy	and	adherence	to	ART,	it	may	be	that	this	group	of	clinicians	may	be	less	inclined	to	aggressively	treat	dyslipidemia.	Additional	research	on	the	uptake	of	these	recommendations	is	certainly	warranted.	Finally,	the	ongoing	REPRIEVE	(Randomized	Trial	to	Prevent	Vascular	Events	in	HIV)	trial	is	designed	to	determine	the	efficacy	of	daily	pitavastatin,	versus	placebo,	in	reducing	the	risk	of	CVD.	Notably,	the	study	population	for	this	trial	includes	HIV	infected	patients	who	do	not	have	an	indication	for	statin	therapy	according	to	the	2013	ACC/AHA	guidelines	for	lipid	lowering	therapy.	
6.5	Conclusion	We	found	similar	uptake	of	statins	among	HIV	infected	women	when	indicated,	as	compared	to	HIV	uninfected	patients,	in	the	Women’s	Interagency	HIV	Study.	The	2013	ACC/AHA	treatment	guidelines,	when	applied	to	a	population	of	HIV	infected	women,	nearly	tripled	the	number	of	women	indicated	for	statin	treatment,	in	comparison	to	the	2001	ATP	III	guidelines.	Statins	were	moderately	effective	in	lowering	LDL	cholesterol	in	both	HIV	infected	and	uninfected	groups.	In	line	with	previous	research,	the	reduction	in	LDL	among	HIV	infected	women	was	less	than	among	HIV	uninfected	women.	
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